



**IASO**

**PRIVATE GENERAL – OBSTETRIC – GYNECOLOGICAL &  
PAEDIATRICS CLINIC – DIAGNOSTIC - THERAPEUTIC &  
RESEARCH CENTER S.A.**

## **ANNUAL FINANCIAL REPORT**

**Of the fiscal year January 1<sup>st</sup> - December 31<sup>st</sup> 2009**

**(In accordance with article 4 of L.3556/2008)**

**Distinctive Title: IASO S.A.**

**37-39 Kifissias Ave. , Maroussi**

**S.A. Registration No: 13366/06/B/86/61**

**[www.iaso.gr](http://www.iaso.gr)**

## Contents

	Page
<b>A. Statements of the members of the Board of Directors .....</b>	<b>3</b>
<b>B. Board of Directors Report .....</b>	<b>4</b>
<b>C. Auditor’s Report .....</b>	<b>22</b>
<b>D. Annual Financial Statements.....</b>	<b>24</b>
<b>E. Data and Information .....</b>	<b>81</b>
<b>F. Information regarding article 10 of L.3401/2005.....</b>	<b>82</b>
<b>G. Availability of Financial Statements .....</b>	<b>83</b>

## A. STATEMENTS OF THE MEMBERS OF THE BOARD

(According to article 4, par. 2 of the Law 3556/2008)

The members of the Board of Directors of IASO S.A:

1. **Georgios Stamatiou** of Ioannis, Chairman
2. **Paraskevas Petropoulos** of Panagiotis, Managing Director
3. **Georgios Mpoulinakis** of Evaggelos, Managing Director,  
specially assigned by the Board of Directors at its meeting of 19/03/2010.

Under our above-mentioned capacity, we state and we assert that to the best of our knowledge:

- I. The annual financial statements of the Company and the Group IASO for the period 01/01/2009 – 31/12/2009, which were prepared in accordance with the International Financial Reporting Standards, describe in a truthful way the assets, the liabilities, the equity and the results of the Company, as well as of the companies' which are included in the consolidation as a total.
- II. The annual report of the Board of Directors describes in a truthful way the progress, performance and the status of IASO, as well as the companies' which are included in the consolidation as a total, including the main risks and uncertainties.

Maroussi, March 19<sup>th</sup> 2010

The asserting,

Chairman of the BoD

Managing Director

Managing Director

Georgios I. Stamatiou  
ID no. K 030874

Paraskevas P.Petropoulos  
ID no. N 317661

Georgios E. Mpoulinakis  
ID no. AB 570398

**B. BOARD OF DIRECTORS REPORT OF  
“IASO PRIVATE GENERAL – OBSTETRIC – GYNECOLOGICAL &  
PAEDIATRICS CLINIC – DIAGNOSTIC - THERAPEUTIC &  
RESEARCH CENTER S.A.”**

ON THE CONSOLIDATED AND PARENT FINANCIAL STATEMENTS  
For the Fiscal Year 01/01 – 31/12/2009

The present Report of the Board of Directors refers to the fiscal year 2009. The report has been written in compliance with the article 4 of L.3556/2007 and the executive decisions of the Hellenic Capital Market Commission.

**I) Progress and performance for FY2009**

The Group’s management, considering the adverse financial status caused by the recession, the deceleration of financial activity, and the decline of the customers purchasing power, decided, within the framework of the corporate social responsibility of the Group, not to increase any of the pricelists of the Group’s companies for the second year in a row .

On the contrary, within the aforementioned policy of corporate responsibility, the group decreased prices during the last two months of 2009 in selected inpatient and outpatient services aiming at maintaining and further increasing the group’s customer base. The combination of the above policies had as an effect the limitation of the financial crisis impact on the Group.

The slight decrease in service demand, in combination with the expected increase in operating expenses due to the start up of IASO Children’s hospital’s departments affected the figures of IASO Group for FY2009, presenting a decrease compared to those of FY2008.

IASO Group posted provisions for possible losses that may occur above the insurance coverage, if some of the lawsuits of third parties against the Group’s companies and the associate physicians favor the suitors against the Group’s companies.


**Consolidated Financial Results**

The consolidated turnover for the FY2009 reached the amount of €178,5 mil, posting an decrease of 3,0% compared with the last year. The consolidated Earnings Before Interest, Taxes, Depreciation & Amortization (EBITDA) reached the amount of €37,5 mil. recording

a decrease of €11,4 mil (23,3%), The decrease is attributed to the formation of provisions amounting € 5,1 mil. for possible losses that may occur above the insurance coverage , if some of the lawsuits of third parties against the Group’s companies and the associate physicians , favor the suitors against the Group’s companies , taking into account the revocation of operating license of the insurance company “ASPIS” .

Therefore the aforementioned EBITDA margin is weakened by 5,56 percentage points compared with the same period last year. Earnings Before Taxes amounted to €26,6 mil. presenting a decrease of 24,3%, while Earnings After Taxes & Minorities Interests (EAT&M) reached the amount of €13,5 mil. posting a decrease of 33,8%. This fact is attributed firstly on the EBIT margin recession by 30,6 % compared with 2008 and secondly on the deletion of part of the deferred tax claims of the subsidiary IASO General. The evolution of the aforementioned figures is illustrated in the following tables:


**Chart 1: IASO Group Brief Financial Results (in mil. €)**



**Chart 2: IASO Group Profit Margins**



Each company’s participation in the formation of the consolidated FY2009 basic financial results is also demonstrated below:



In the following table some of the basic indices of the group are presented:

Consolidated Ratios	2009	2008
EBITDA ( % on revenues)	21,02%	26,58%
EBIT ( % on revenues)	16,00%	22,37%
Owner's Equity / Total Assets *	0,35	0,38
Owner's Equity / Total Liabilities *	0,54	0,61
Owner's Equity / Bank Liabilities *	0,94	1,07

\*Note: These ratios can be further improved if the consolidated cash and cash equivalent (amounted to €20,16 mil. on 31/12/2009) get subtracted from total assets.

More specifically per company the following are observed:


### IASO S.A.

The turnover for the first FY2009 amounted to €106,2 mil versus €109,0 mil for the FY2008, posting a decrease of 2,58%. The increase of turnover is attributed to: a ) The company while presenting a marginal decrease in inpatients by 0,3%, is posting a decrease of inpatient revenues by 1,9%, due to the differentiation of the patient mix because of the addition of the pediatric cases, that during the FY2008 existed only in the fourth quarter and b)The outpatient cases presented a decrease of 3,2%, with the corresponding outpatient revenue decreasing by 5,1%, due to the differentiation of the patient mix, with the average revenue per outpatient pediatric case being decreased in comparison with IASO Maternity revenue per case. EBITDA posted a decrease by €7,66 mil (19,31%) from €39,7 mil. to €32,0 mil. This decrease is attributed mainly to the formation of provisions amounting € 4,3 mil for possible losses that may occur above the insurance coverage, if some of the lawsuits of third parties against the company and the associate physicians, favor the suitors against the company taking into account the revocation of operation license of the insurance


company “ASPIS” . Secondly the decrease is attributed to the lack of price increases, the prices decreases in the last two months of 2009 as well as the increased operating expenses due to the inauguration of the pediatric clinic’s departments. The Earnings before taxes, amounted to €26,36 mil versus €32,8 in the corresponding last year period, presenting a decrease of 19,63%, due to the addition of the aforementioned provisions and operating expenses and depreciation of the pediatric clinic in the cost. The Earnings after taxes amounted to €17,2 mil in the FY2009 versus €24,8 mil in the FY2008 posting a decrease of 30,9% and following the trend of the company’s earnings before taxes.

The evolution of the above figures is presented in the following charts:


**Chart 4:** In & Outpatient IASO SA (in thousands)




**Chart 5:** IASO SA Average Revenue per patient



**Chart 6:** IASO SA Brief Financial Results (in mil. €)



**Chart 7:** IASO SA Profit Margins



Some of the most important financial ratios of the Company are demonstrated in the following table:

<b>Parent Company Ratios</b>	<b>2009</b>	<b>2008</b>
EBITDA ( % on revenues)	30,2%	36,4%
EBIT ( % on revenues)	25,3%	32,6%
Owner's Equity / Total Assets *	0,57	0,58
Owner's Equity / Total Liabilities *	1,32	1,36
Owner's Equity / Bank Liabilities *	2,24	2,25

\* Note: These ratios can be further improved if the Company's cash and cash equivalent (amounted to €6,5 mil. on 31.12.2009) get subtracted from total assets.

The above indices present a decrease in comparison with the corresponding FY2008 for the reasons mentioned in the above analysis.

### **IASO General S.A.**

IASO General's Revenues for the FY2009 were recorded at €67,8 mil. presenting a decrease of 3,9% vs last year's figures. The decrease in the revenues is attributed to: a) the decrease of inpatient cases by 3,6%, with revenues decrease of inpatients by 4,8 %, reflecting the change in patient mix .Additionally, while the outpatient cases increased by 9,9%, rewarding the management's efforts in this direction, the revenues of outpatients presented an increase by 4,1% due to the decrease of the average revenue per patient by 5,3%. EBITDA decreased by €3,4 mil (39,35%), from €8,5 mil to €5,2 mil as a result of : a) Not increasing the prices, b) The expected annual increases of operating expenses, c) the formation of provisions amounting € 0,8 mil for possible losses that may occur above the insurance coverage, if some of the lawsuits of third parties against the company and the associate physicians, favor the suitors against the company taking into account the revocation of operation license of the insurance company "ASPIS" as well. Earnings Before Tax reached the amount of €0,6 mil. vs €3,7 mil. in the FY2008. This slight decrease of earnings before taxes is attributed to the significant decrease of the financial expenses by 59,4% , as a consequence of the decrease of the company's borrowings and the interest rates.

As far as Net Profit After Taxes is concerned, losses recorded amount to € 3,0 mil. vs losses amounting to €2.3 mil. for the corresponding period of 2008, caused by deferred tax adjustments due to the expiration of the 5 year period.

### **MedStem Services S.A.**

The subsidiary company MedStem Services S.A. presented a marginal increase in Revenues of 0,5%, compared with the last year, reaching the amount of €4,7 mil, despite the decline in stem cell storages caused by the recession, due to the increase of revenue from the “AMVROSIA” cafeteria. Earnings before Interest, Taxes, Depreciation & Amortization (EBITDA) reached the amount of €1,3 mil. vs €1,1 mil. in 2008 posting an increase of 22,4%, despite the Group’s policy of not increasing prices, due to the increase of other revenue while Earnings After Taxes reached the amount of €0,80 mil. presenting an increase of 18,2% compared with the corresponding last year period.

**The other subsidiaries** have not commenced their activities yet.

### **Group’s Expenses**

The administrative and marketing overheads reached, for the FY2009, the amount of €11,8 mil. presenting an increase of 2,6%, which is mainly attributed to the formation of provisions amounting € 2,8 mil. for possible losses that may occur above the insurance coverage, as mentioned, to the IASO Children’s hospital commencement of operations, the increase of payroll cost and the increase of various rates.

Financial expenses presented a decrease in the first six months of 2009 amounting to € 2,6 mil. vs € 7,3 mil. in the same period of 2008 reflecting the interest rates significant decrease and despite the raise of total borrowings.

### **Borrowings – Cash and cash equivalents**

The Group’s borrowings amounted to €144,25 mil at 31/12/2009 vs €122,25 mil on 31/12/2008 posting an increase of 18,0% , due to the progress in the investment program concerning the financing of the project of construction and equipment of IASO THESSALIAS S.A.. The cash and cash equivalents of the Group on 31/12/2009 amounted to €20,16 mil. vs €23,36 mil. on 31/12/2008.

### **Personnel**

The total number of personnel employed by the Group on 31/12/2009 amounted to 1.701 persons versus 1.659 on 31/12/2008 and the Company 1.019 and 1.008 persons on

31/12/2009 and 31/12/2008 correspondingly, due to the hiring of the necessary staff for IASO Children's hospital and the initial staffing of IASO THESSALIAS S.A.

## **II) Important corporate developments of 2009**

a) The parent Company, according to the contract signed on 07/11/2008, for the issuance of a common bond loan (revolving) proceeded, on 16/02/2009, in the issuance of a 2<sup>nd</sup> bond series of total amount € 2.500.000,00 in order to finance its investment plan and other needs which are in progress. The parent company IASO SA invested during 2009 a total of €9,82 mil €, which include the new modern operating room complex that started operations within the last quarter of 2009 and the expansion and modernization of the kitchen.

b) The subsidiary company IASO THESSALIAS S.A. following the agreement signed on 15/02/2008, for the issuance of a common bond loan, proceeded, on 16/02/2009, in the issuance of a 4th bond series of total amount € 3.500.000,00 in order to finance the construction of buildings for the completion of the company's clinic and the purchase of medical and hotel equipment. On 03/03/2009 the share capital increase of the company was completed, in spite of the international economic downturn and the financial crisis, with the participation of 12 new local physicians along with the existing ones. The total funds raised amounted to € 8.500.002,00 representing 100% of the share capital increase.

c) IASO S.A., on 19/03/2009, announced that its subsidiary company IASO OF SOUTHERN SUBURBS S.A. and the construction company INTRAKAT S.A. signed a memorandum of cooperation for the construction of a clinic in the municipality of Agios Ioannis Redis. The budget of this project is € 70 mil. On 22/05/2009 a preliminary contract was signed regarding the purchase of a piece of land of 12.680 sq.m., which belongs INTRAKAT S.A., in execution of the relevant term of the aforementioned memorandum of cooperation. According to the terms of the aforementioned preliminary contract the seller is obliged to acquire all relevant permits for the construction of the clinic within a period of 11 months (including extension provision) from the date of signing the aforementioned contract. With regards to the use of land for hospitalization, we are waiting for the receipt of the official opinion of the supreme administrative court, in order to take our final decisions.

d) Upon resolution of the Extraordinary Meeting of shareholders of the subsidiary company "IASO THESSALIAS S.A." held on 04.04.2009, it was decided the share capital increase by € 5.493.324,00 by cash, through the issuance of 2.746.662 new registered shares of nominal value € 2,00 each and issue price € 3,50. The arising Share Premium Reserve

amounted to € 4.119.993,00 (1799/06.05.2009 Decision of Larissa Prefecture). The share capital increase was successfully concluded on 06/07/2009, with the participation of 6 new doctors in addition to the existing doctors shareholders. The amount of funds raised through the share capital increase was €9.613.317,00

e) IASO S.A. and ETHNIKI GENERAL INSURANCE CO contracted on 16/04/2009 for the hospitalization of insured patients by ETHNIKI GENERAL INSURANCE CO in IASO Children's clinic, a fact considered to be significantly important as far as the attraction of new cases is concerned along with the increase of the clinic's occupancy. Within the framework of the above insurance contract a cover of 90% of the hospitalization expenses is offered to all children that are born at IASO Maternity hospital, without insurance fees for the 1<sup>st</sup> year.

### **III) Perspectives – evolution of activities for 2010**

Group's standard policy is not to announce -publish business plans and provisions apart from signed agreements or BoD's decisions regarding the implementation of specific business plans. Group's management has adjusted its development and improvement policies by examining and evaluating the consequences along with the opportunities emerging from the international financial crisis. The management of the Group looks towards 2010 and the following years with sobriety and measured optimism. The small elasticity that Greek healthcare services demand presents, the devotion to our values, our well-established strengths, foremost among them being our customers' loyalty and the dedication of our doctors and personnel, allows us to believe that the negative impact of the current crisis will be limited.

Among the management targets is the continuous increase of outpatients, for all companies of the Group, with further improvement of occupancy ratio in IASO General as well as the increase of cases of IASO Children's hospital and the increase of stem cells and cord blood storages of MedStem Services.

Moreover, the completion of IASO Thessalias clinic's construction and beginning of operation by the end of March 2010 (as we have already mentioned in the past) belongs to the Group's strategic geographical expansion outside the Attica region. Through the new clinic in the region of Thessaly the Group implements its development strategy for new state-of-the-art equipment and buildings, the combination of which, aims to provide high quality services and high level customers' satisfaction.

The new hospital will operate maternity, general and paediatric departments with fully developed diagnostic sector .It will also operate intensive care units (adults and newborns), operating rooms (surgeries and delivery rooms), pathological department, Haemodialysis Unit and laboratories.

For the next two years the basic target for IASO Thessalias is the attraction of inpatients and outpatients via a) the existing doctors-shareholders as well as new associate doctors, which will be the medical personnel b) the private customers for the attraction of which the company will utilize IASO's strong reputation, experience, know-how and specialization and c) the health insurance funds by signing relevant contracts.

Next investment target is the construction of a clinic in the municipality of Agios Ioannis Redis, by the subsidiary IASO of Southern Suburbs. The budget of this project is € 70 mil.

On the 19.03.2009 a memorandum of cooperation for the construction of a clinic has been signed with the construction company INTRAKAT S.A. for the construction of a hospital at the municipality of Agios Ioannis Redis, with a total budget of €70 mil. In execution of a relevant term in the 19.03.2009 a memorandum of cooperation, on the 22.05.2009 a preliminary contract was signed for the purchase of a piece of land of 12.680 sq.m. property of Intrakat in the municipality of Agios Ioannis Redis. According to the aforementioned memorandum INTRAKAT has an obligation to acquire all the necessary permits for the construction of the clinic within a period of 11 months from the date of signing the contract. With regards to the use of land for hospitalization, we are waiting for the receipt of the official opinion of the supreme administrative court, in order to take our final decisions.

#### **IV) Main risks and uncertainties for 2010**

Group's policy consists of constant supervision of the developments taking place in Greece as well as abroad. Our objective is to avoid possible negative effects that may arise, however, during 2010 the Group could be affected by:

**A) Health Care Services Demand.** In spite the fact that in the past, demand for private health care services has shown a relatively low elasticity, political, financial and social changes, instability and fluctuations in Greece, Europe or worldwide may eventually affect demand. According to the European Commission's interim forecast of February 2010, the growth and inflation rates are expected to reach 0,7% and 1,1% respectively, in the euro zone. The implementation of the Stability Programme for the limitation of the fiscal deficit,

with the cuts in salaries within the broader public sector along with the changes in taxation, are expected to have a negative impact on the consumer disposable income and is possible to affect the demand for private health care services.

The severe international financial crisis that is still in progress has caused significant consequences to the private insurance companies. A further deterioration of the insurance companies' status, which would cause a possible discontinuance of insurance coverage towards its customers, would affect indirectly the Group's services demand.

**B) Inflation – Interest Rates.** According to the latest European commission interim forecasts the inflationary trends are expected to be relatively stable, with the forecasts being marginally increased to 1,1% for the euro zone. European Commission's intentions, according to its officers are to maintain the interest rates at low levels, so as to boost the economic activity and reverse the unfavorable economic conditions. All of the existing loan contracts are Euro denominated and are based on floating Euribor interest rates. The result of the Management's decision to follow a floated interest rates policy was for the Group, to benefit from the Euribor rates decline, which begun on October 2008 and continue until today. From a sensitivity analysis perspective an interest rate decrease by 1,00% would decrease the Group's financial expenses for the first six months of 2010 by approximately € 0,8 mil., while an equivalent interest rate increase by 1,00% would increase affect the Group's financial expenses by approximately € 0,8 mil for the same period. All the Group's bank loans are based on fixed spread rates. Spread rates for the open accounts are being periodically revised.

**C) Capital Markets Risk.** The fluctuations of the international and Greek capital markets, as well as the investors' psychology influence the course of IASO's share. Furthermore, it should also be taken into consideration that ATHEX has lower liquidity as compared to other major international markets, which may cause difficulties in the effort to sell shares, particularly in large blocks. Sale of a large number of the Company's shares, or estimations or articles that such a sale may take place, is possible to affect the share's price.

**D) Operating Risk.** Possible legislative changes can affect the expansion policy of the Group. In addition, potential bed capacity additions in the region of Attica along with potential incapability to successfully keep up with the medical and technological developments, could negatively affect the Group's financial status and operating results.

**E) Foreign Currency Risk.** Substantial and immediate foreign currency risk does not exist for the Group, since all the Group's activities are taking place inside the euro zone. All the Group's borrowings are in euro.

**F) Liquidity Risk.** Financial risk management plays a very significant role within the Group's total risk management policy. The Group's financial instruments consist mainly of deposits with banks, trade accounts receivable and payable, transactions with, related parties, stock equity investments and dividends payable. The interest rate risk exposure for bank liabilities and investments is continuously monitored on a budgetary base. Regarding the proper management of the liquidity, this is achieved through a combination of available cash flows, approved bank credit lines and strict monitoring of cash flows overall. It is noted that, on 31/12/2009, the Group's cash in hand amounted to € 20,16 mil. plus sufficient approved undrawn credit lines that can be utilized to fund short -medium term liabilities.

### **Risk Management**

IASO Group applies methodologies in order to identify, assess, measure and monitor all risks deriving from on and off-balance sheet items, as well as from all its operations, systems and procedures of the Group companies, as well as the external environment parameters that could negatively affect the unimpeded operations and financial status .

### **Operating and Business Risk**

The Group has taken action regarding the operating risk management. More specifically:

**1) Insurance Coverage.** All the Group's active companies are covered by insurance contracts that are currently in force and renewed when expired, covering:

- a. Its tangible assets and its premises
- b. Civil, Employer's, Professional (malpractice) Liability
- c. Group IASO Employees
- d. Group IASO Motor vehicles.
- e. Loss of Income
- f. Cash theft & burglary

The insurance coverage varies by category of insurance risk and objective, within a framework that the management has set as fair and adequate. Moreover, the Group

management has adopted the policy of requiring the associate doctors to proceed to self insurance coverage for professional (malpractice) liability.

- 2) Management of Receivables – Liabilities and IT Systems.** The Group keeps a backup data base, while significant resources have been invested for the purchase and installation of equipment and development of systems for the storage and recovery of business information in order to secure the Group's receivables and business continuity. The Group's management continuously audits receivables and updates the credit control procedures. The Group receivables come from sales to private customers, social security funds and insurance companies. Receivables from social security funds and insurance companies have a minimum loss risk. Potential credit risk is mainly related to private customers. The Group's Management posts provisions for coverage of possible bad debts and incorporates them the balance sheet as well as in the Financial Statements. All of the above financial assets that are presented in the financial statements have been impaired (incorporating the relevant provisions) and are of high credit quality.
- 3) Unaudited tax years.** All of the group's companies have adjusted their tax claims and liabilities in order to present as at 31/12/2009 the net equity positions of the Company and the Group with clarity. For this reason at 31/12/2009 a part of the Group's deferred taxes expected benefits that stem from losses of the FY2004 have been written off. Additionally within the FY2009 for the unaudited fiscal years the cumulative provision for tax differences and penalties reached the amounts of €1,38 mil and €1,47 mil for the Company and the Group respectively.
- 4) Technological Developments.** The health services as well as the market position of each health care services provider, greatly depend on the technological competence and the supremacy of the biomedical equipment being used. Group's top priority has been to continuously invest in programs aiming at renewing and purchasing state-of-the-art medical equipment.
- 5) Large Customer Dependence.** The Group has no dependence to large customers like insurance companies and social insurance providers.

## **V) Transactions with related parties**

The Company's important transactions with related parties, pursuant to IAS 24, concern the Company's transactions with its subsidiaries (related companies within the meaning of article 42e of Codified Law 2190/20). These transactions are the following:

"IASO" PRIVATE GENERAL – OBSTETRIC – GYNECOLOGICAL & PAEDIATRICS CLINIC – DIAGNOSTIC - THERAPEUTIC & RESEARCH CENTER S.A.

1) On 03/03/2009, the share capital increase, through cash payment with preemption rights in favor of the existing shareholders, of the subsidiary company IASO THESSALIAS S.A. was completed. The aforementioned share capital increase was decided on 01/11/2008 by the Extraordinary Shareholders Meeting of the company and took place from 01/11/2008 until 03/03/2009. Following that, the share capital of the company increased by €4.857.144,00 through the issuance of 2.428.572 new common registered shares with voting rights, of nominal value € 2,00 each and issue price € 3,50. In the aforementioned share capital increase and for the period 01/01/2009-30/06/2009, the parent company participated with the amount of € 1,00 while the Group companies IASO GENERAL S.A. and MEDSTEM SERVICES S.A. participated with the amount of €2.000.001,50 and € 727.321,00 respectively.

2) Upon resolution of the Extraordinary Meeting of shareholders of the subsidiary company IASO THESSALIAS S.A. held on 04.04.2009, it was decided to increase the share capital by € 5.493.324,00 in cash, through the issuance of 2.746.662 new registered shares of nominal value € 2,00 each and issue price € 3,50. In the aforementioned share capital increase and for the period 01/01/2009-30/06/2009, the Group's company IASO General S.A. participated by the amount of € 4.000.003,00.

3) The collected dividend from the subsidiary company MEDSTEM SERVICES S.A., was €765.000,00 or €75,00 per share. The above dividend was collected by the parent company (€ 757.350,00) and the subsidiary IASO GENERAL S.A. (€ 7.650,00).

## **Information of par.7 and Explanatory Report of par.8 of article 4 of Law 3556/2007**

### **Structure of the Company's Share Capital**

The Company's share capital amounts to € 23.388.223,32 divided in 53.155.053 common registered shares bearing a vote right, each one of nominal value of € 0,44.

The Company's shares are listed for trading in the Securities Market (Big Capitalization Category) of Athens Exchange.

Each share provides for all rights contemplated by the law and the Company's articles of association, and in specific:

(a) The right on the dividend from the Company's annual or wind up profits. A proportion of 35% of net profits, deducting only the regular reserve, is distributed to the shareholders from the profits of every fiscal year, as a first dividend while the granting of an additional dividend is decided by the General Meeting.

Every shareholder is entitled to a dividend on the dividend cut-off date. Each share's dividend is paid to the shareholder not later than two months after the Annual General Meeting approving the Annual Financial Statements.

The means and place of payment is announced through the Press and on the Daily Price Bulletin on the ATHEX website.

The right to collect the dividend is prescribed after 5 years from the end of the year during which the General Meeting approved the dividend's distribution, and the corresponding amount is paid to the Greek State.

(b) The right to receive contribution during wind up or capital depreciation corresponding to the share, respectively, provided that the General Meeting reaches such decision.

(c) Preemption right in every share capital increase of the Company through cash amounts and subscription to new shares or through issuance of bonds which are convertible to shares.

(d) The right to receive copies of the financial statements and Chartered Auditors reports and reports of the Company's Board of Directors.

(e) The right to submit a request to the Company at least five (5) full days before the General Meeting, so that the Company's Board of Directors submit to the General Meeting the specific information requested with respect to the Company matters, to the extent that these are useful for the actual assessment of the subjects of the agenda.

(f) The right to participate in the General Meeting in which each share gives the right to one vote.

(g) The right to exit the Company by offering shares, in the case where the person who submitted the takeover offer for the acquisition of the total number of shares according to law 3461/2006, afterwards the submission of the takeover offer, holds at least 90% of the Company's voting rights.

(h) The shareholders General Meeting reserves all its rights during wind up.

Shareholders shall not be held liable beyond the nominal capital of each share.

#### **Limitations concerning the transfer of the Company's shares**

Transfer of the Company's shares takes place in accordance to the descriptions of the law and no limitations are set forth by its Articles of Association concerning transferring of shares, given the fact that they are dematerialized shares listed in the Athens Stock Exchange.

#### **Significant direct or indirect holdings in the sense of articles 9 to 11 of L.3556/2007**

As of 31.12.2009, EUROMEDICA S.A. has a proportion of 10% of the Company's share capital. No other person or legal entity owns participation greater than 5% of the share capital.

#### **Owners of shares granting special control rights**

There are no Company's shares granting special control rights.

#### **Limitations in voting rights**

There are no limitations in the voting rights.

#### **Company's shareholders agreements concerning the transfer of the Company's shares or limitations in voting rights**

To the best of the Company's knowledge, there are no agreements between its shareholders limiting the transfer of shares or the exercise of voting rights deriving from the Company's shares.

#### **Rules regarding appointment and replacement of the members of the Board of Directors and amendment of the Articles of Association.**

The rules set forth in the Company's Articles of Association for the appointment and replacement of the members of the Board of Directors are no different from Law 2190/20.

The Company is managed by a Board of Directors composed of a minimum of eleven (11) and a maximum of thirteen (13) members, elected from the General Meeting for a term of

three years which may be extended automatically until the time of the first regular General Meeting after the expiry of their term.

The Company has made use of the possibility given by the article 18, paragraphs 7 and 8, of the Law 2190/20 and in the Company's Articles of Association is provided for the replacement of members of the Board of Directors the possibility of election of substitute members and the possibility for the remaining members to continue the management without replacing the missing members.

Particularly in the article 6 paragraph 1 of the Company's Articles of Association it is predicted that should a vacancy result due to a member's death, resignation or any other reason, then the remaining members may continue with the managing of the company without replacing the missing members, provided that they are at least three and that their number exceeds the half of the members' number before the vacancy.

Moreover, in the article 6 paragraph 2 of the Company's Articles of Association it is stated that in any case, the remaining members of the Board of Directors, as long as they are at least three, may elect new members to replace those missing. The above election is valid for the rest of the term of the member being replaced. The decision on the election is subject to the publicity formalities of article 7b of Law 2190/20 and is announced by the Board of Directors to the following General Meeting. The following General Meeting may replace the elected members, even if no such subject has been provided in the Meeting's agenda.

As far as it concerns the rules for amendment of the Company's Articles of Association, these are no different from Law 2190/20.

**Board of Directors or its members competence in respect of issuance of new shares or purchase of own shares according to the article 16 of L.2190/1920.**

(a) According to the provisions of article 13 par. 1 sec. b' and c' of law 2190/20 and article 4 of the Company's Articles of Association, through a decision of the General Meeting which is subject to the publicity formalities of article 7b of the Law 2190/20, the Board of Directors has the right by virtue of a decision that is taken with a minimum majority of two-thirds (2/3) of its total members, to increase the share capital in part or in full up to the capital amount that is paid up on the date this power is granted by the General Meeting. The above power of the Board of Directors is renewable by the General Meeting for a period not longer than five years per each renewal and effective after the completion of

each five-year period. This decision of the General Meeting is subject to the publicity formalities of article 7b of Law 2190/20.

(b) If however the Company's reserves exceed  $\frac{1}{4}$  of the paid-up share capital, then a decision of the General Meeting is always required and must be taken in the special quorum and majority set forth in article 29 par. 3 and 4 and 31 par. 2 of Law 2190/20 as currently in force.

(c) According to the provisions of article 13 par. 13 of Law 2190/20, as amended by article 19 of law 3604/2007, by virtue of a decision of the General Meeting of Shareholders, taken according to the provisions of par. 3&4 of article 29 and par. 2 of article 31, a stock option program may be established amongst the members of the Board of Directors and the Company's personnel, as well as amongst the related companies as defined in par. 5 of article 42e of Law 2190/20, in the form of stock option under the special terms of the aforementioned decision, a summary of which is subject to the formalities of article 7b of Law 2190/20. Persons providing services to the company in a constant base may also be designated as entitled to stock options. The decision of the General Meeting in question, specifically designates the number of shares that may be issued -which may not exceed  $\frac{1}{10}$  of existing shares, according to the law – if the persons entitled to purchase shares exercise such right, the price and the terms of the disposal of the shares to those entitled to receive them, the persons entitled to purchase shares or the categories of them and the method of determination of price of acquisition, without prejudice to the par. 2 of article 14 of Law 2190/20, the duration of the stock options program, as well as every other relevant term. With the same decision, the General Meeting of the Shareholders may assign to the Board of Directors to define the beneficiaries or the categories of the beneficiaries, the conditions of exercising their rights and every other term regarding the stock options program. The Board of Directors, through a decision, regulates all other details, not being otherwise regulated by the General Meeting, issues the share purchase rights Certificates and at least every trimester delivers the share-titles already issued or issues and delivers the share-titles to the persons having exercised their right (to purchase shares), increasing the Company's share capital and certifying such increase. The decision of the Board of Directors certifying the payment of the share capital increase must be taken every trimester, contrary to article 11 of Law 2190/20. These decisions of share capital increase are not considered amendments to the Articles of Association and paragraphs 7-11 of article 13 of Law 2190/20 are not applicable thereat. The Board of Directors is compelled at the last

month of each financial year, during which share capital increases were decided, according to the above, to adapt with its decision the article relevant to the share capital of the Articles of Association, in order to reflect the increase of the share capital occurred after the above increases, respecting the publication procedure provided in article 7b of Law 2190/20.

(d) According to the article 16 of Law 2190/20, as amended by article 21 of law 3604/2007, the Company itself or a person acting on behalf of the Company may acquire its own shares, only after consent of the General Meeting of the Shareholders under the special terms and procedures provided in article 16 of Law 2190/20.

**Material agreements activated, amended or terminated in case of a change in the control of the Company, following a public offer.**

There are no agreements activated, amended or terminated in case of change of control following public proposition

**Company's Agreements with members of the Board of Directors or the Company's personnel.**

There are no agreements with members of the Board of Directors or the Company's personnel, containing payment of remuneration especially in case of resignation or discharge, without a valid reason or expiry of term in office or employment due to a tender offer.

We presented to you the Parent Company and the Consolidated Financial Statements for the fiscal year January 1st to December 31st 2009, in comparison with the same period of 2008. We submitted the Auditor's Report, according to the law for Société Anonyme (S.A.), and we ask you to approve the financial statements and release the members of the Board of Directors and the Auditor of any responsibility for the fiscal year ended at the 31st of December 2009.

Maroussi, 19<sup>th</sup> of March 2010

Georgios I. Stamatou  
Chairman of the Board of Directors

## **C. INDEPENDENT AUDITOR’S REPORT**

To the Shareholders of “IASO S.A.”

PRIVATE GENERAL – OBSTETRIC – GYNECOLOGICAL & PAEDIATRICS CLINIC  
– DIAGNOSTIC - THERAPEUTIC & RESEARCH CENTER

### **Report on Stand-alone and Consolidated Financial Statements**

We have audited the accompanying stand alone and consolidated financial statements of “IASO S.A.” PRIVATE GENERAL – OBSTETRIC – GYNECOLOGICAL & PAEDIATRICS CLINIC – DIAGNOSTIC - THERAPEUTIC & RESEARCH CENTER and its subsidiaries, which comprise the stand alone and consolidated financial position as at 31 December 2009, and the stand alone and consolidated statements of comprehensive income, changes in equity and cash flows for the year then ended, and a summary of significant accounting policies and other explanatory notes.

### **Management's Responsibility for the company Stand-alone and Consolidated Financial Statements**

Management is responsible for the preparation and fair presentation of these stand-alone and consolidated financial statements in accordance with International Financial Reporting Standards as adopted by the European Union and for such internal controls as management determines is necessary to enable the preparation of stand-alone and consolidated financial statements that are free from material misstatement, whether due to fraud or error.

### **Auditor's Responsibility**

Our responsibility is to express an opinion on these stand-alone and consolidated financial statements based on our audit. We conducted our audit in accordance with International Standards of Auditing. Those standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance whether the stand-alone and consolidated financial statements are free from material misstatement. An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the stand-alone and consolidated financial statements, whether due to fraud or error. In making those risk assessments, the

auditor considers internal control relevant to the entity's preparation and fair presentation of the stand-alone and consolidated financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity's internal control. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of accounting estimates made by management, as well as evaluating the overall presentation of the stand-alone and consolidated financial statements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

### **Opinion**

In our opinion, the accompanying stand-alone and consolidated financial statements present fairly, in all material respects, the financial position of the Company and of its subsidiaries as of December 31, 2009, and of their financial performance and their cash flows for the year then ended in accordance with International Financial Reporting Standards as adopted by the European Union.

### **Report on Other Legal and Regulatory Requirements**

We confirm that the information given in the Directors' Report is consistent with the accompanying stand alone and consolidated financial statements and complete in the context of the requirements of articles 43a, and 37 of Codified Law 2190/1290.



**BAKER TILLY HELLAS**

Certified Public Accountants A.E.

396, Mesogion Avenue

15341 Ag.Paraskevi-Athens, Greece

SOEL Reg.No: 148

Athens, 23th March 2010

The Certified Public Accountant

Ioannis Toliopoulos

SOEL. Reg. No: 12381

## D. ANNUAL FINANCIAL STATEMENTS

<b><u>Contents of the Financial Statements</u></b>	<b>Page</b>
Statement of Financial Position of the Company and the Group as at 31/12/2009 .....	26
Statement of Comprehensive Income of the Company and the Group as at 31/12/2009 ....	27
Cash Flow Statement of the Company and the Group as at 31/12/2009 .....	29
Statement of Changes in Equity of the Company and the Group as at 31/12/2009.....	30
Notes to the Financial Statements .....	32
<b>1. General information .....</b>	<b>32</b>
<b>2. Summary of significant accounting policies .....</b>	<b>32</b>
2.1 Basis of preparation of the financial statements .....	32
2.2 Consolidation .....	39
2.3 Segment reporting.....	39
2.4 Foreign currency conversion .....	40
2.5 Property, plant and equipment .....	40
2.6 Intangible assets.....	42
2.7 Construction contracts .....	43
2.8 Investments .....	43
2.9 Inventories .....	43
2.10 Trade receivables .....	44
2.11 Cash and cash equivalents .....	44
2.12 Share capital.....	44
2.13 Borrowings .....	45
2.14 Deferred income tax .....	45
2.15 Employee benefits .....	45
2.16 Provisions .....	46
2.17 Revenue recognition .....	46
2.18 Leases .....	47
2.19 Dividend Distribution .....	47
2.20 Government grants.....	47
<b>3. Financial risk management.....</b>	<b>48</b>
3.1 Fair value estimation.....	48

3.2 Financial Risk .....	48
<b>4. Critical accounting estimates and judgements.....</b>	<b>48</b>
4.1 Critical accounting estimates and assumptions .....	49
<b>5. Information by business unit .....</b>	<b>49</b>
<b>6. Property, plant and equipment .....</b>	<b>53</b>
<b>7. Intangible assets .....</b>	<b>56</b>
<b>8. Inter-company transactions.....</b>	<b>58</b>
8.1 Inter-company transactions.....	58
8.2 Investments to subsidiaries .....	60
<b>9. Available-for-sale financial assets .....</b>	<b>62</b>
<b>10. Other financial assets at fair value through profit or loss .....</b>	<b>63</b>
<b>11. Trade and other receivables .....</b>	<b>63</b>
<b>12. Inventories .....</b>	<b>64</b>
<b>13. Cash and cash equivalents .....</b>	<b>64</b>
<b>14. Borrowings .....</b>	<b>64</b>
14.1 Net borrowings .....	66
<b>15. Trade and other payables .....</b>	<b>67</b>
<b>16. Retirement benefit obligations.....</b>	<b>68</b>
<b>17. Other operating income (gains).....</b>	<b>69</b>
<b>18. Finance costs - net.....</b>	<b>70</b>
<b>19. Income tax expense .....</b>	<b>70</b>
<b>20. Earnings per share.....</b>	<b>72</b>
<b>21. Dividends per share .....</b>	<b>73</b>
<b>22. Expenses by nature.....</b>	<b>73</b>
<b>23. Guarantees.....</b>	<b>77</b>
<b>24. Share capital.....</b>	<b>77</b>
<b>25. Other long-term receivables .....</b>	<b>77</b>
<b>26. Other non-current liabilities.....</b>	<b>78</b>
<b>27. Other non-current provisions.....</b>	<b>78</b>
<b>28. Other operating expenses.....</b>	<b>79</b>
<b>29. Reserves at fair value- Other reserves .....</b>	<b>79</b>
<b>30. Events after the balance sheet date .....</b>	<b>80</b>

**STATEMENT OF FINANCIAL POSITION OF THE GROUP AND THE  
COMPANY AS AT 31/12/2009**

		<b>THE GROUP</b>	<b>THE GROUP</b>	<b>THE</b>	<b>THE</b>
	<i>NOTE</i>	<b>31/12/2009</b>	<b>31/12/2008</b>	<b>COMPANY</b>	<b>COMPANY</b>
				<b>31/12/2009</b>	<b>31/12/2008</b>
<b>ASSETS</b>					
<b>Non-current assets</b>					
Property, plant and equipment	6	293.754.875,81	261.990.376,40	134.093.125,61	129.530.544,09
Intangible assets	7	1.556.370,87	1.556.846,35	1.113.347,96	1.012.669,45
Investments in subsidiaries	8.2	0,00	0,00	129.053.234,86	121.985.730,36
Other long-term receivables	25	901.818,82	805.761,35	80.084,04	74.932,04
		<b>296.213.065,50</b>	<b>264.352.984,10</b>	<b>264.339.792,47</b>	<b>252.603.875,94</b>
<b>Current assets</b>					
Inventories	12	5.438.901,43	5.465.581,38	2.357.564,88	2.753.862,66
Trade receivables	11	38.736.277,78	34.866.199,56	6.566.583,75	5.374.029,81
Other receivables	11	18.690.416,03	12.154.759,03	11.958.854,83	11.318.837,08
Available-for-sale financial assets	9	4.189.927,64	4.189.927,64	4.189.927,64	4.189.927,64
Other financial assets at fair value through profit or loss	10	451.485,51	363.916,07	451.485,51	363.916,07
Cash and cash equivalents	13	20.164.800,15	23.362.891,30	6.428.387,65	6.157.697,72
		<b>87.671.808,54</b>	<b>80.403.274,98</b>	<b>31.952.804,26</b>	<b>30.158.270,98</b>
<b>TOTAL ASSETS</b>		<b>383.884.874,04</b>	<b>344.756.259,08</b>	<b>296.292.596,73</b>	<b>282.762.146,92</b>
		<b>THE GROUP</b>	<b>THE GROUP</b>	<b>THE</b>	<b>THE</b>
		<b>31/12/2009</b>	<b>31/12/2008</b>	<b>COMPANY</b>	<b>COMPANY</b>
				<b>31/12/2009</b>	<b>31/12/2008</b>
<b>LIABILITIES</b>					
<b>EQUITY</b>					
Share capital (53.155.053 shares x 0.44€)	24	23.388.223,32	23.388.223,32	23.388.223,32	23.388.223,32
Share premium account	24	42.497.459,83	42.497.459,83	42.497.459,83	42.497.459,83
Reserves at fair value	29	65.756.493,43	65.756.493,43	40.842.266,55	40.842.266,55
Other reserves	29	8.256.157,46	6.975.781,65	7.724.230,95	6.480.570,89
Retained earnings		-17.986.854,32	-18.051.089,12	53.925.596,38	49.671.980,46
<b>Total equity of Company's equity holders</b>		<b>121.911.479,72</b>	<b>120.566.869,11</b>	<b>168.377.777,03</b>	<b>162.880.501,05</b>
Minority interest	8.2	13.094.903,19	9.798.981,32	0,00	0,00
<b>Total equity</b>		<b>135.006.382,91</b>	<b>130.365.850,43</b>	<b>168.377.777,03</b>	<b>162.880.501,05</b>
<b>LIABILITIES</b>					
<b>Non-current liabilities</b>					
Borrowings	14	121.850.000,00	114.250.000,00	69.750.000,00	66.750.000,00
Deferred income tax liabilities	19	17.200.041,33	14.480.323,29	12.905.677,87	13.690.711,85
Retirement benefit obligations	16	5.062.763,98	4.761.022,27	3.211.100,82	3.024.056,90
Other non-current liabilities	26	5.726.161,08	4.554.611,76	57.505,42	68.854,75
Other non-current provisions	27	8.007.175,10	1.896.904,36	6.299.312,88	1.836.904,36
		<b>157.846.141,49</b>	<b>139.942.861,68</b>	<b>92.223.596,99</b>	<b>85.370.527,86</b>
<b>Current liabilities</b>					
Trade and other payables	15	58.801.000,61	58.019.814,31	20.660.892,80	20.937.487,12
Current income tax liabilities	19	9.831.349,03	8.427.732,66	9.530.329,91	8.073.630,89
Short-term borrowings	14	22.400.000,00	8.000.000,00	5.500.000,00	5.500.000,00
		<b>91.032.349,64</b>	<b>74.447.546,97</b>	<b>35.691.222,71</b>	<b>34.511.118,01</b>
<b>Total Liabilities</b>		<b>248.878.491,13</b>	<b>214.390.408,65</b>	<b>127.914.819,70</b>	<b>119.881.645,87</b>
<b>Total Equity and Liabilities</b>		<b>383.884.874,04</b>	<b>344.756.259,08</b>	<b>296.292.596,73</b>	<b>282.762.146,92</b>

The accompanying notes constitute an integral part of the annual financial statements.

**STATEMENT OF COMPREHENSIVE INCOME OF THE GROUP AND THE  
COMPANY AS AT 31/12/2009**

	Note	THE GROUP		THE GROUP	
		1/1-31/12/2009	1/1-31/12/2008	1/10-31/12/2009	1/10-31/12/2008
Sales	5	178.499.627,08	183.996.867,78	44.773.378,20	46.496.023,08
Cost of sales	22	137.868.131,97	134.880.082,46	35.532.033,40	34.292.780,79
<b>Gross profit</b>		<b>40.631.495,11</b>	<b>49.116.785,32</b>	<b>9.241.344,80</b>	<b>12.203.242,29</b>
Other operating income	17	6.241.432,16	4.284.930,92	1.607.352,99	1.097.969,39
Administrative expenses	22	-6.474.913,87	-5.568.179,09	-2.118.081,70	-1.715.471,74
Selling and marketing costs	22	-5.337.224,48	-5.904.570,10	-1.565.321,75	-2.474.120,75
Other operating expenses	28	-6.502.144,09	-764.784,74	-853.900,78	-94.182,34
<b>Earnings before taxes, financing, investing results and depreciation – amortization (EBITDA)</b>		<b>37.514.851,06</b>	<b>48.907.133,98</b>	<b>8.606.068,01</b>	<b>11.136.357,28</b>
Amortization – Depreciation	6,7,22	-8.956.206,23	-7.742.951,68	-2.294.674,45	-2.118.920,44
<b>Earnings before taxes, financing, investing results (EBIT)</b>		<b>28.558.644,83</b>	<b>41.164.182,30</b>	<b>6.311.393,56</b>	<b>9.017.436,84</b>
Finance costs – profit	18	629.112,89	1.291.472,45	16.965,52	246.924,31
Finance costs – expenses	18	-2.572.460,54	-7.287.318,90	-438.300,97	-1.924.760,62
Other finance results		0,00	0,00	0,00	0,00
Profit/loss from related parties		0,00	0,00	0,00	0,00
<b>Profit before taxes</b>		<b>26.615.297,18</b>	<b>35.168.335,85</b>	<b>5.890.058,11</b>	<b>7.339.600,53</b>
Income tax expense	19	-13.099.140,05	-14.753.110,49	-6.283.626,80	-7.341.250,37
<b>Profit/Loss after taxes (A)</b>		<b>13.516.157,13</b>	<b>20.415.225,36</b>	<b>-393.568,69</b>	<b>-1.649,84</b>
<u>Attributable to:</u>					
Equity holders of the Company	20	13.737.272,98	20.619.768,34	-236.413,58	220.803,74
Minority interest (loss)		-221.115,85	-204.542,98	-157.155,11	-222.453,58
<b>Other comprehensive income after taxes (B)</b>	22	0,00	2.060.928,13	0,00	2.060.928,13
<b>Total comprehensive income after taxes (A)+(B)</b>		<b>13.516.157,13</b>	<b>22.476.153,49</b>	<b>-393.568,69</b>	<b>2.059.278,29</b>
<u>Attributable to:</u>					
Equity holders of the Company		13.737.272,98	22.638.724,00	-236.413,58	2.255.468,29
Minority interest (loss)	22	-221.115,85	-162.570,51	-157.155,11	-196.190,00
<b>Profit/Loss after taxes per share – basic (expressed in €)</b>	20	0,2584	0,4259	-0,0044	0,0424

The accompanying notes constitute an integral part of the annual financial statements.

	Note	THE COMPANY		THE COMPANY	
		1/1-31/12/2009	1/1-31/12/2008	1/10-31/12/2009	1/10-31/12/2008
Sales	5	106.237.701,28	109.051.880,43	26.517.750,19	28.361.846,86
Cost of sales	22	72.876.863,75	69.725.517,83	18.803.120,43	19.057.514,79
<b>Gross profit</b>		<b>33.360.837,53</b>	<b>39.326.362,60</b>	<b>7.714.629,76</b>	<b>9.304.332,07</b>
Other operating income	17	4.546.847,01	3.057.818,87	1.260.333,72	961.237,39
Administrative expenses	22	-4.151.159,07	-3.833.769,48	-1.249.912,92	-1.137.309,27
Selling and marketing costs	22	-2.454.293,75	-2.929.057,30	-834.127,73	-1.184.026,40
Other operating expenses	28	-4.390.857,76	-31.264,46	-642.841,39	-5.251,13
<b>Earnings before taxes, financing, investing results and depreciation – amortization (EBITDA)</b>		<b>32.058.674,91</b>	<b>39.728.215,32</b>	<b>7.573.442,67</b>	<b>9.162.547,71</b>
Amortization – Depreciation	6,7,22	-5.147.300,95	-4.138.125,09	-1.325.361,23	-1.223.565,05
<b>Earnings before taxes, financing, investing results (EBIT)</b>		<b>26.911.373,96</b>	<b>35.590.090,23</b>	<b>6.248.081,44</b>	<b>7.938.982,66</b>
Finance costs – profit	18	1.038.730,76	1.489.761,00	-44.440,12	24.846,18
Finance costs – expenses	18	-1.584.419,99	-4.275.744,45	-263.964,24	-1.222.130,45
Other finance results		0,00	0,00	0,00	0,00
Profit/loss from related parties		0,00	0,00	0,00	0,00
<b>Profit before taxes</b>		<b>26.365.684,73</b>	<b>32.804.106,78</b>	<b>5.939.677,08</b>	<b>6.741.698,39</b>
Income tax expense	19	-9.174.297,09	-7.930.905,60	-3.943.428,77	-1.361.995,96
<b>Profit/Loss after taxes (A)</b>		<b>17.191.387,64</b>	<b>24.873.201,18</b>	<b>1.996.248,31</b>	<b>5.379.702,43</b>
<u>Attributable to:</u>					
Equity holders of the Company	20	17.191.387,64	24.873.201,18	1.996.248,31	5.379.702,43
Minority interest (loss)		0,00	0,00	0,00	0,00
<b>Other comprehensive income after taxes (B)</b>		0,00	-283.757,87	0,00	-283.757,87
<b>Total comprehensive income after taxes (A)+(B)</b>		<b>17.191.387,64</b>	<b>24.589.443,31</b>	<b>1.996.248,31</b>	<b>5.095.944,56</b>
<u>Attributable to:</u>					
Equity holders of the Company		17.191.387,64	24.589.443,31	1.996.248,31	5.095.944,56
Minority interest (loss)		0,00	0,00	0,00	0,00
<b>Profit/Loss after taxes per share – basic (expressed in €)</b>	20	0,3234	0,4626	0,0376	0,0959

The accompanying notes constitute an integral part of the annual financial statements.

**CASH FLOW STATEMENT OF THE GROUP AND THE COMPANY**  
**AS AT 31/12/2009**

	<b>THE GROUP</b>		<b>THE COMPANY</b>	
	<b>1/1-31/12/2009</b>	<b>1/1-31/12/2008</b>	<b>1/1-31/12/2009</b>	<b>1/1-31/12/2008</b>
<b>Cash Flows from Operating Activities</b>				
Profit for the period	26.615.297,18	35.168.335,85	26.365.684,73	32.804.106,78
Adjustments to profit	17.982.118,24	15.139.269,21	10.643.251,50	7.623.763,69
	<b>44.597.415,42</b>	<b>50.307.605,06</b>	<b>37.008.936,23</b>	<b>40.427.870,47</b>
<b>Adjustments of working capital</b>				
Decrease/(increase) inventories	26.679,95	-486.012,86	396.297,78	-789.818,62
Decrease/(increase) receivables	-9.592.829,70	-11.247.897,53	-2.991.484,82	1.139.083,35
Decrease/(increase) of other current assets	-451.345,71	68.582,85	-5.152,00	322.296,54
Increase/(decrease) of payable accounts (except banks)	3.159.935,16	12.747.693,16	315.951,20	5.338.050,52
Outflow of provisions	-609.031,64	0,00	-460.698,57	0,00
	-7.466.591,94	1.082.365,62	-2.745.086,41	6.009.611,79
<b>Net cash generated from operating activities</b>	<b>37.130.823,48</b>	<b>51.389.970,68</b>	<b>34.263.849,82</b>	<b>46.437.482,26</b>
<b>Cash flows from operating Activities</b>				
Interest paid	-3.185.323,26	-6.559.906,96	-2.235.202,59	-3.860.371,88
Income tax paid	-10.044.939,04	-9.437.399,41	-9.648.292,32	-8.833.453,84
<b>Cash flow generated from (used in) Operating Activities (A)</b>	<b>23.900.561,18</b>	<b>35.392.664,31</b>	<b>22.380.354,91</b>	<b>33.743.656,54</b>
<b>Cash flows from Investing Activities</b>				
Purchase of property, plant and equipment (PPE)	-40.598.114,34	-33.679.332,37	-9.535.210,58	-11.100.856,05
Purchases of intangible assets	-331.782,15	-488.649,08	-286.252,14	-352.559,78
Disposal of PPE	100.963,35	109.452,12	35.839,82	5.758,72
Purchases of Available-for-sale financial assets	0,00	0,00	0,00	0,00
Purchases of financial assets at fair value through profit or loss	0,00	-101.470,40	-4.567.504,50	-31.462.981,36
Adjustment of derivative financial assets	0,00	0,00	0,00	0,00
Disposal of available-for-sale financial assets	0,00	0,00	0,00	0,00
Disposal of financial assets at fair value through profit or loss	0,00	320.200,00	0,00	2.744.710,00
Interest received	541.543,45	1.291.472,45	951.161,32	1.489.761,00
Proceeds from repayments of borrowings from related parties	0,00	0,00	0,00	0,00
Proceeds from grants	150.706,38	39.555,25	72.757,12	39.555,25
<b>Net cash generated from (used in) Investing Activities (B)</b>	<b>-40.136.683,31</b>	<b>-32.508.772,03</b>	<b>-13.329.208,96</b>	<b>-38.636.612,22</b>
<b>Cash Flows from Financing Activities</b>				
Share capital increase/ decrease	2.818.487,00	1.997.860,54	0,00	0,00
Disposal of treasury shares	0,00	0,00	0,00	0,00
Dividends paid to Company's shareholders	-11.780.456,02	-14.685.610,50	-11.780.456,02	-14.685.610,50
Raised borrowings	30.000.000,00	30.500.000,00	8.500.000,00	16.000.000,00
Repayments of borrowings	-8.000.000,00	-24.776.492,62	-5.500.000,00	-2.750.000,00
Payments of finance lease capital	0,00	0,00	0,00	0,00
<b>Net cash generated from (used in) Financing Activities (C)</b>	<b>13.038.030,98</b>	<b>-6.964.242,58</b>	<b>-8.780.456,02</b>	<b>-1.435.610,50</b>
<b>Net (decrease)/ increase in cash and cash equivalents (A+B+C)</b>	<b>-3.198.091,15</b>	<b>-4.080.350,30</b>	<b>270.689,93</b>	<b>-6.328.566,18</b>
<b>Cash and cash equivalents at beginning of period</b>	<b>23.362.891,30</b>	<b>27.443.241,60</b>	<b>6.157.697,72</b>	<b>12.486.263,90</b>
<b>Cash and cash equivalents at end of period</b>	<b>20.164.800,15</b>	<b>23.362.891,30</b>	<b>6.428.387,65</b>	<b>6.157.697,72</b>

**STATEMENT OF CHANGES IN EQUITY OF THE GROUP AND THE COMPANY AS AT 31/12/2009**

**THE GROUP**

	Share Capital	Paid-in surplus	Legal reserves	Revaluation reserves	Retained earnings/losses	Total	Minority Interests	Total equity
<b>Balance on January 1<sup>st</sup> 2008</b>	<b>23.360.015,00</b>	<b>42.525.668,15</b>	<b>5.854.191,15</b>	<b>64.591.565,30</b>	<b>-25.009.462,31</b>	<b>111.321.977,29</b>	<b>8.896.044,52</b>	<b>120.218.021,81</b>
Profit for the period	0,00	0,00	0,00	0,00	21.489.504,76	<b>21.489.504,76</b>	-178.279,40	<b>21.311.225,36</b>
<b>Total Comprehensive Income</b>	<b>0,00</b>	<b>0,00</b>	<b>0,00</b>	<b>0,00</b>	<b>21.489.504,76</b>	<b>21.489.504,76</b>	<b>-178.279,40</b>	<b>21.311.225,36</b>
Share capital issue	28.208,32	-28.208,32	0,00	0,00	0,00	<b>0,00</b>	1.997.860,54	<b>1.997.860,54</b>
Acquisition of subsidiaries' shares	0,00	0,00	0,00	0,00	0,00	<b>0,00</b>	-101.470,40	<b>-101.470,40</b>
Legal reserves	0,00	0,00	1.121.590,50	0,00	-1.121.590,50	<b>0,00</b>	0,00	<b>0,00</b>
Evaluation of property at fair value	0,00	0,00	0,00	1.164.928,13	0,00	<b>1.164.928,13</b>	0,00	<b>1.164.928,13</b>
Dividends	0,00	0,00	0,00	0,00	-14.544.915,00	<b>-14.544.915,00</b>	0,00	<b>-14.544.915,00</b>
Effect from increase/decrease of % participation on subsidiaries	0,00	0,00	0,00	0,00	1.135.373,93	<b>1.135.373,93</b>	-1.135.373,93	<b>0,00</b>
Disposal of subsidiaries' shares	0,00	0,00	0,00	0,00	0,00	<b>0,00</b>	320.200,00	<b>320.200,00</b>
<b>Balance on December 31<sup>st</sup> 2008</b>	<b>23.388.223,32</b>	<b>42.497.459,83</b>	<b>6.975.781,65</b>	<b>65.756.493,43</b>	<b>-18.051.089,12</b>	<b>120.566.869,11</b>	<b>9.798.981,32</b>	<b>130.365.850,43</b>
<b>Balance on January 1<sup>st</sup> 2009</b>	<b>23.388.223,32</b>	<b>42.497.459,83</b>	<b>6.975.781,65</b>	<b>65.756.493,43</b>	<b>-18.051.089,12</b>	<b>120.566.869,11</b>	<b>9.798.981,32</b>	<b>130.365.850,43</b>
Profit for the period	0,00	0,00	0,00	0,00	13.737.272,98	<b>13.737.272,98</b>	-221.115,85	<b>13.516.157,14</b>
<b>Total Comprehensive Income</b>	<b>0,00</b>	<b>0,00</b>	<b>0,00</b>	<b>0,00</b>	<b>13.737.272,98</b>	<b>13.737.272,98</b>	<b>-221.115,85</b>	<b>13.516.157,14</b>
Share capital issue	0,00	0,00	0,00	0,00	0,00	<b>0,00</b>	2.818.487,00	<b>2.818.487,00</b>
Legal reserves	0,00	0,00	1.280.375,81	0,00	-1.280.375,81	<b>0,00</b>	0,00	<b>0,00</b>
Dividends	0,00	0,00	0,00	0,00	-11.694.111,66	<b>-11.694.111,66</b>	0,00	<b>-11.694.111,66</b>
Effect from increase/decrease of % participation on subsidiaries	0,00	0,00	0,00	0,00	-698.550,71	<b>-698.550,71</b>	698.550,71	<b>0,00</b>
<b>Balance on December 31<sup>st</sup> 2009</b>	<b>23.388.223,32</b>	<b>42.497.459,83</b>	<b>8.256.157,46</b>	<b>65.756.493,43</b>	<b>-17.986.854,32</b>	<b>121.911.479,72</b>	<b>13.094.903,19</b>	<b>135.006.382,91</b>

"IASO" PRIVATE GENERAL – OBSTETRIC – GYNECOLOGICAL & PAEDIATRICS CLINIC – DIAGNOSTIC - THERAPEUTIC & RESEARCH CENTER S.A.

**THE COMPANY**

	Share Capital	Paid-in surplus	Legal reserves	Revaluation reserves	Retained earnings/losses	Total	Minority Interests	Total equity
<b>Balance on January 1<sup>st</sup> 2008</b>	23.360.015,00	42.525.668,15	5.384.038,15	41.126.024,42	40.440.227,02	152.835.972,74	0,00	152.835.972,74
Profit for the period	0,00	0,00	0,00	0,00	24.873.201,18	24.873.201,18	0,00	24.873.201,18
<b>Total Comprehensive Income</b>	<b>0,00</b>	<b>0,00</b>	<b>0,00</b>	<b>0,00</b>	<b>24.873.201,18</b>	<b>24.873.201,18</b>	<b>0,00</b>	<b>24.873.201,18</b>
Share capital issue	28.208,32	-28.208,32	0,00	0,00	0,00	0,00	0,00	0,00
Legal reserves	0,00	0,00	1.096.532,74	0,00	-1.096.532,74	0,00	0,00	0,00
Evaluation of property at fair value	0,00	0,00	0,00	-283.757,87	0,00	-283.757,87	0,00	-283.757,87
Dividends	0,00	0,00	0,00	0,00	-14.544.915,00	-14.544.915,00	0,00	-14.544.915,00
<b>Balance on December 31<sup>st</sup> 2008</b>	<b>23.388.223,32</b>	<b>42.497.459,83</b>	<b>6.480.570,89</b>	<b>40.842.266,55</b>	<b>49.671.980,46</b>	<b>162.880.501,05</b>	<b>0,00</b>	<b>162.880.501,05</b>
<b>Balance on January 1<sup>st</sup> 2009</b>	<b>23.388.223,32</b>	<b>42.497.459,83</b>	<b>6.480.570,89</b>	<b>40.842.266,55</b>	<b>49.671.980,46</b>	<b>162.880.501,05</b>	<b>0,00</b>	<b>162.880.501,05</b>
Profit for the period	0,00	0,00	0,00	0,00	17.191.387,64	17.191.387,64	0,00	17.191.387,64
<b>Total Comprehensive Income</b>	<b>0,00</b>	<b>0,00</b>	<b>0,00</b>	<b>0,00</b>	<b>17.191.387,64</b>	<b>17.191.387,64</b>	<b>0,00</b>	<b>17.191.387,64</b>
Legal reserves	0,00	0,00	1.243.660,06	0,00	-1.243.660,06	0,00	0,00	0,00
Dividends	0,00	0,00	0,00	0,00	-11.694.111,66	-11.694.111,66	0,00	-11.694.111,66
<b>Balance on December 31<sup>st</sup> 2009</b>	<b>23.388.223,32</b>	<b>42.497.459,83</b>	<b>7.724.230,95</b>	<b>40.842.266,55</b>	<b>53.925.596,38</b>	<b>168.377.777,03</b>	<b>0,00</b>	<b>168.377.777,03</b>

The accompanying notes constitute an integral part of the annual financial statements.

**NOTES TO THE ANNUAL FINANCIAL STATEMENTS OF THE  
FISCAL YEAR ENDED AT 31/12/2009**

**1. General information**

The company “IASO” PRIVATE GENERAL, OBSTETRIC – GYNECOLOGICAL & PAEDIATRICALS CLINIC – DIAGNOSTIC - THERAPEUTIC & RESEARCH CENTER S.A. (“the Company”) and its subsidiaries

1. IASO GENERAL CLINIC OF HOLARGOS S.A.
2. IASO MACEDONIAS GROUP OF NORTHERN GREECE S.A.
3. IASO OF SOUTHERN SUBURBS GENERAL CLINIC – PRIVATE OBSTETRICS S.A.
4. MODERN MULTIFUNCTIONAL REHABILITATION-RESTORATION CENTER S.A.
5. IASO HEALTH ENTERPRISES S.A.
6. MEDSTEM HEALTH SUPPORT SERVICES S.A.
7. IASO THESSALIAS GENERAL CLINIC – PRIVATE OBSTETRICS S.A.

(hereunder the Group) are engaged in providing health services.

The company “IASO” PRIVATE GENERAL, OBSTETRIC – GYNECOLOGICAL & PAEDIATRICALS CLINIC – DIAGNOSTIC - THERAPEUTIC & RESEARCH CENTER S.A., is a Société Anonyme (S.A.) and is listed on the Athens Stock Exchange. The address of its registered office is in Maroussi, 37 – 39, Kifissias Avenue, and its website address is [www.iaso.gr](http://www.iaso.gr).

The Annual Financial Statements of 31/12/2009 have been approved by the Board of Directors on 19/03/2010.

**2. Summary of significant accounting policies**

**2.1 Basis of preparation of the financial statements**

The accounting policies and methods of calculation applied in the current annual financial statements are the same to those applied for the preparation of the audited annual financial statements for the previous fiscal years.

In the year 2003 and 2004 the International Accounting Standards Board (IASB) issued a series of new International Financial Reporting Standards (IFRS) and revised the International Accounting Standards (IAS), which in combination with the existing un-revised standards issued by the International Accounting Standards Committee (IASC – International Accounting Standards Board IASB), are referred to as “The IFRS Stable Platform 2005”. The Group adopts “The IFRS Stable Platform 2005” from 1 January 2005.

### **Adoption of IAS No. 1 (Revised 2003)**

The application of the IAS 1 (revised 2003) lead to the reform of the presentation of the financial statements. The minority interests are presented henceforth in a separate row in the items of the Net Equity. Profit and loss attributable to the minority shareholders and those attributable to the Company’s equity holders are presented henceforth as allocation of the net result for the period.

The preparation of financial statements in conformity with IFRS requires the use of certain critical accounting estimates and exercise of judgement in the process of applying the following accounting policies.

The financial statements of the parent company and its subsidiaries have been prepared under the historical cost convention, besides land and buildings, which have been measured at fair value and are analytically described below.

### **New standards, interpretations and amendments to published standards**

The financial statements have been prepared with the same accounting policies of the prior financial year, except the following new standards and interpretations that had to be adopted as of 1 January 2009.

### **I. Standards and interpretations mandatory for the fiscal year 2009**

**IFRS 7 (Amendment) “Financial Instruments - Disclosures” - Reclassification of Financial Assets** (applicable on or after 1 July 2008)

The amended standard requires additional disclosures about fair value measurement and liquidity risk. Fair value measurements related to items recorded at fair value are to be disclosed by the source of inputs, using a three-level hierarchy, by class, for all financial instruments recognized at fair value. In addition, reconciliation between the beginning and ending balance for level 3 fair value measurements is now required, as well as significant transfers between the levels in the fair value hierarchy. The amendments also clarify the requirements for liquidity risk disclosures with respect to derivative transactions and assets used for liquidity management. This amendment will have no impact on the financial statements of the Company and the Group.

**IAS 1 (Revised in 2007) “Presentation of Financial Statements”** (applicable for annual periods beginning on or after 1 January 2009)

The revised standard requires that the statement of changes in equity includes only transactions with shareholders; introduces a new statement of comprehensive income that combines all items of income and expense recognized in profit or loss together with “other comprehensive income” (either in one single statement or in two linked statements); and requires the inclusion of a third column on the balance sheet to present the effect of restatements of financial statements or retrospective application of a new accounting policy as at the beginning of the earliest comparative period. The Group and the Company made the necessary changes to the presentation of its financial statements in 2009 and has elected to present the statement of comprehensive income in two related statements.

**IAS 23 “Borrowing Cost” (Revised in 2007)**

This Standard supersedes the previous version of IAS 23. The substantial difference with respect to the previous standard relates to removing the option of immediately expensing the borrowing costs directly attributable to the acquisition of qualifying assets that necessarily take a substantial period of time to get ready for their intended use or sale. Such borrowing costs shall now be capitalized as part of the cost of that asset. Amendments also to IFRS 1, IAS 1, IAS 7, IAS 11, IAS 16, IAS 38 and IFRIC 1 were made and are applicable on or after 1 January 2009. The Company and the Group will apply IAS 23 from 1 January 2009.

**IAS 32 (Amendment) “Financial Instruments: Presentation” and IAS 1 (Amendment) “Presentation of Financial Statements” – Financial Instruments available by the holder (or “puttable instrument”)**

The amendment to IAS 32 requires some financial instruments available by the holder (“puttable”) and obligations arising on liquidation to be classified as equity if specified criteria are met. The amendment to IAS 1 requires disclosure of specified information about the “puttable” instruments classified as equity, since the Company and the Group do not hold such instruments these amendments will have no impact on the financial statements for the year 2009.

**IFRS 1 (Amendment) “First-time Adoption of I.F.R.S” and IAS 27 (Amendment) “Consolidated and Separate Financial Statements”** (applicable for annual periods beginning on or after 1 January 2009)

The amendment to IFRS 1 permits entities when adopting IFRS for the first time to use as deemed cost either the fair value or the carrying amounts reported under previous GAAP for the measurement of the initial cost of an investment in a subsidiary, jointly controlled entity and associate. Also, the amendment abolishes the cost method defined by IAS 27 and replaces it by requiring dividends to be presented as income in the investor’s separate financial statements. There were made amendments also to IAS 18, IAS 21 and IAS 36 which are also applicable for periods beginning on or after 1 January 2009. Since the parent company and its subsidiaries have already adopted the IFRS this amendment will have no impact on the financial statements for the year 2009.

**IFRS 2 (Amendment) “Share based Payment” – Non – vesting conditions**

The amendment clarifies the definition “vesting conditions” introducing the term “non-vesting conditions” for terms that do not relate to length of service or achievement of performance. It also clarifies that for all cancellations deriving either from the entity or the contracting parties shall be applied the same accounting treatment. (This amendment has not yet been endorsed by the EU).

This amendment will have no impact on the financial statements of the Company and the Group for the year 2009.

**IFRS 8 – “Operating Segments”** (applicable for annual periods beginning on or after 1 January 2009)

This standard replaces IAS 14 under which segments were recognised and reported on the basis of an analysis of risks and returns. According to IFRS 8 operating segments are components of an entity about which separate financial information is available that is evaluated regularly by the Managing Director/Chief Operating Decision Maker and presented in the financial statements on the same basis as that used for internal reporting purposes. The Company and the Group will apply IFRS 8 from 1 January 2009.

**IFRIC 13 “Customer Loyalty Programmes”** (applicable for annual periods beginning on or after 1 July 2008)

Interpretation 13 clarifies the accounting for companies granting some kind of customer loyalty incentive such as “loyalty points” or “free travelling miles” to customers buying goods or services. This interpretation is not relevant for the Company’s and the Group’s operations.

**IAS 39 (Amendment) “Financial Instruments: Recognition and Measurement”**

The changes in this standard are the following:

- a) It is possible to have transfers to and from the class of fair value through profit or loss when a derivative is qualified or derecognised as cash flow hedging instrument or as net investment hedging.
- b) The definition of financial asset or financial liability at fair value through profit or loss as regard to assets held for trading has been amended. It is clarified that a financial asset or a financial liability that is part of a portfolio of identified financial instruments that are managed together and for which there is evidence of a recent actual pattern of short-term profit-taking, is included in such a portfolio on initial recognition.
- c) The applicable guidance for designation and documentation of the hedging relationship for hedge accounting purposes indicates that a hedging instrument shall involve a party external to the reporting entity and reports one segment as example of an entity. This means that in order to be applied the hedge accounting at segment level, the requirements for hedge accounting shall be met at the same time by the segment that applies it. The amendment eliminates this requirement so as the IAS 39

to co-exist with the IFRS 8 “Operating segments” which requires the disclosure about reportable segments to rely on the information provided to the Managing Director/Chief Operating Decision Maker.

- d) When it is re-measured the carrying amount of a debit hedged item and discontinued the hedge accounting of fair value, the amendment clarifies that shall be used a revised effective interest rate (calculated on the date the hedge accounting of fair value was discontinued).

The Company and the Group apply IAS 39 (Amendment) since 1 January 2009. This is not expected to have any impact on the financial statements.

## **II. Standards and interpretations mandatory after the fiscal year 2009**

**IFRS 3 (Revised) “Business Combinations” and IAS 27 (Amended) “Consolidated and Separate Financial Statements”** (effective for annual periods beginning on or after 1 July 2009)

The revised IFRS 3 introduces a number of changes in the accounting for business combinations which will impact the amount of goodwill recognized, the reported results in the period that an acquisition occurs, and future reported results. Such changes include the expensing of acquisition-related costs and recognizing subsequent changes in fair value of contingent consideration in the profit or loss. The amended IAS 27 requires that a change in ownership interest of a subsidiary to be accounted for as an equity transaction. Furthermore the amended standard changes the accounting for losses incurred by the subsidiary as well as the loss of control of a subsidiary. The changes introduced by these standards must be applied prospectively and will affect future acquisitions and transactions with minority interests. The Group will apply these changes from their effective date.

**IFRS 9 “Financial Instruments” - Phase 1 financial assets, classification and measurement** (effective for annual periods beginning on or after 1 January 2013)

Phase 1 of this new IFRS introduces new requirements for classifying and measuring financial assets. Early adoption is permitted. This standard has not yet been endorsed by the EU.

**IAS 32 (Amendment) Classification on Rights Issues** (effective for annual periods beginning on or after 1 February 2010).

This amendment relates to the rights issues offered for a fixed amount of foreign currency which were treated as derivative liabilities by the existing standard. The amendment states that if certain criteria are met, these should be classified as equity regardless of the currency in which the exercise price is denominated.

**IAS 24 (Revised) Related Party Disclosures** (effective for annual periods beginning on or after 1 January 2011).

This revision relates to the judgment which is required so as to assess whether a government and entities known to the reporting entity to be under the control of that government are considered a single customer. In assessing this, the reporting entity shall consider the extent of economic integration between those entities. Early application is permitted and adoption shall be applied retrospectively. This interpretation has not yet been endorsed by the EU.

**IFRIC 14 (Amendment) Prepayments of a Minimum Funding Requirement** (effective for annual periods beginning on or after 1 January 2011).

The purpose of this amendment was to permit entities to recognize as an asset some voluntary prepayments for minimum funding contributions. This earlier application is permitted and must be applied retrospectively. This amendment has not yet been endorsed by the EU.

Since the Company and the Group do not have such benefit programs for their employees, this interpretation will have no impact on the financial statements of the Group and the Company.

**IFRIC 17 “Distributions of non-cash assets to owners”** (effective for annual periods beginning on or after 1 July 2009)

The interpretation provides guidance on how to account for non-cash distributions to owners. The interpretation clarifies when to recognize a liability, how to measure it and the associated assets, and when to derecognize the asset and liability.

**IFRIC 19 “Extinguishing Financial Liabilities with Equity Instruments”** (effective for annual periods beginning on or after 1 July 2010)

This interpretation addresses the accounting treatment when there is a renegotiation between the entity and the creditor regarding the terms of a financial liability and the creditor agrees to accept the entity’s equity instruments to settle the financial liability fully or partially. IFRIC 19 clarifies such equity instruments are “consideration paid” in accordance with paragraph 41 of IAS 39. As a result, the financial liability is derecognized and the equity instruments issued are treated as consideration paid to extinguish that financial liability. This interpretation has not yet been endorsed by the EU.

## **2.2 Consolidation**

### **Subsidiaries**

An audit is achieved over which the Company has the power to govern the financial and operating policies of another entity with the intention of gain from its activities. The consolidated financial statements comprise the financial statements of the company as well as the entities audited by the company (its subsidiaries) at the end of the relevant fiscal year and they are not consolidated at the date that control ceases. The financial statements of the subsidiaries have been changed where necessary to ensure consistency with the policies adopted by the Group. Inter-company transactions, balances, income and expenses are eliminated at consolidation.

## **2.3 Segment reporting**

A business segment is a group of assets and operations engaged in providing products and services that are subject to risks and returns that are different from those of other business segments. The Group of companies IASO provides mainly health services, which comprise of hospital, diagnostic, therapeutic and research activities. The results of the operating units are regularly monitored by the persons in charge of taking operating decisions for the unit, in cooperation with the Board of Directors, in order to evaluate the units’ performance and resources allocation.

## **2.4 Foreign currency conversion**

### **A) Functional and presentation currency**

Items included in the financial statements of the Group's companies, are presented in their financial environment's currency, where every company operates (official currency). The consolidated financial statements are presented in euro, which is the official currency adopted by the Group's companies.

### **B) Transactions and balances**

Foreign currency transactions are translated into the functional currency using the exchange rates prevailing at the dates of the transactions. Foreign exchange gains and losses resulting from the settlement of such transactions and from the translation at the year-end exchange rates of monetary assets and liabilities denominated in foreign currencies are recognised in the income statement.

## **2.5 Property, plant and equipment**

Property, plant and equipment, excluding the productive property, are shown at cost less the accumulated depreciation and impairment losses. Cost includes all directly attributable expenditure for the acquisition of the items.

Subsequent costs are included in the asset's carrying amount or recognised as a separate asset, as appropriate, only when it is probable that future economic benefits associated with the item will flow to the Group and the cost of the item can be measured reliably. All repairs and maintenance are charged to the income statement during the financial period in which they are incurred.

Productive property is shown at fair value, based on valuations by independent evaluators, less subsequent accumulative depreciation and impairment losses. The property is revaluated at regular time intervals so that the carrying amounts do not differ from the fair values at the balance sheet closing dates.

On each balance sheet date, the Group reviews the carrying amounts of tangible and intangible assets to determine whether there is any indication that such assets have suffered an impairment loss. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss (if any). Where it is not possible to assess the recoverable value of a specific asset, the Group estimates the recoverable value of the cash-generating unit to which the asset belongs.

Recoverable amount is the higher of fair value less costs to sell and respective value in use. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset for which the estimates of future cash flows have not been adjusted.

If the recoverable amount of an asset (or cash-generating unit) is estimated to be less than its carrying amount, the carrying amount of the asset (cash-generating unit) is reduced to its recoverable amount. An impairment loss is immediately recognized in the income statement, unless the relative asset is been readjusted, in which case, the impairment loss is handled as a reduction to the amount of readjustment.

Where an impairment loss subsequently reverses, the carrying amount of the asset (cash-generating unit) is increased to the revised estimate of its recoverable amount, but so that the increased carrying amount does not exceed the carrying amount that would have been determined had no impairment loss been recognised for the asset (cash-generating unit) in prior years. A reversal of an impairment loss is recognised as income immediately, unless the relative asset is been readjusted, in which case, the reversal of the impairment loss is handled as an increase to the amount of readjustment.

When assets are sold, the adjustments between the value received and their book value is recorded as gains or losses in the income statement. For the operating assets estimated in fair values, the current revaluation reserve included in equity during the sale, is transferred retained earnings. The assets' residual values and useful lives are reviewed if appropriate, at the Management's judgement. In case assets' book values overrun the recoverable amount of the assets, the adjustments (impairment) are recorded as expenses in the income statement. Land is not depreciated. Depreciation on other assets is calculated using the straight-line method to allocate their cost or revaluated amounts to their residual values over their estimated useful lives, as follows:

<b>PROPERTY, PLANT AND EQUIPMENT</b>	<b>YEARS</b>
Buildings (Main building of Maternity Clinic)	50
Machinery	5-30
Wireless communication network	30
High-tech machinery	5
Medium technology machinery	14
Special machinery	20
Vehicles	5-7
Passenger vehicles & motorcycles	5

Lorries	7
Other equipment	3-20
Furniture	20
Utensils	15
Office machines	10
Computers & electronic complexes	5
Telecommunication equipment	3

The productive property or those assets that their use has not yet been determined and are still at construction stage, are shown at cost less any impairment losses. The cost includes professional fees and borrowing costs. The depreciation of this property as well as of the Group's commences when the property is ready for use.

## **2.6 Intangible assets**

### **Trademarks and licenses**

Trademarks and licenses are carried at cost less accumulated amortization. Amortization is calculated using the straight-line method over their estimated, useful lives as follows:

#### **Production and exploitation licences**

Licence for exploitation of IASO General Clinic	50 years
Purchase of IASO trademark	20 years

### **Computer software – other intangible assets**

Acquired computer software licenses are measured at acquisition cost less amortization. The amortization is carried out on a straight-line basis over their estimated useful lives which are as follows:

SAP R3 (the basic business computer software)	10 years
LIS (Central laboratory programme)	5 years
RIS (Radiology software support)	5 years
ASTRAIA (Embryonic software support)	5 years
MUSE, QA (Cardiology department)	5 years
MS OFFICE, WINDOWS 2000, XP, MS, MONEY	3 years

Costs associated with developing and maintaining computer software programmes are recognised as an expense to the fiscal year they incurred.

## **2.7 Construction contracts**

The construction projects of the Group are auctioned, and then having carried out negotiations with the tenderers, the one with the lowest price wins the contract. The contracts prior to their signing are examined by the Legal, the Finance and the New Projects Department, then they are approved by the Board of Directors and are signed by the authorized members. The supervision and audit of the contracts' completion is done by the Finance and New Projects Departments.

## **2.8 Investments**

### **Available-for-sale financial assets**

Available-for-sale financial assets include non-derivatives and more particularly Mutual fund Units. They are included in current assets, except for maturities greater than 12 months after the balance sheet date, which are classified as non current assets. Available-for-sale financial assets and financial assets at fair value through profit or loss are subsequently carried at fair value. Gains or losses from changes in the fair value of the “financial assets at fair value through profit or loss” category are recognised in the income statement in the period in which they arise. The fair values of shares listed in Official Capital Markets are based on current bid prices at balance sheet closing dates. If the market for a financial asset is not active, the Group establishes fair value by using valuation techniques, at balance sheet closing dates.

## **2.9 Inventories**

The inventories are reported at the lower value between the cost and the net realisable value. Cost is determined using the weighted average cost formula. Net realisable value is the estimated selling price of the inventories in the ordinary course of business of the Group companies decreased by the cost of sale and the distribution expenses. Provisions are made for obsolete and damaged inventories with low turnover. The decrease in the cost of inventories to the net realizable value and all other damage to the inventories are posted in the P&L of the period in which they appear.

## **2.10 Trade receivables**

Trade receivables are recognised at their actual value less impairment losses (loss from doubtful receivables). The amount of the provision is recognised in the income statement. Provision for doubtful receivables is conducted when there is objective evidence that the Group will not be able to collect all amounts due, according to the terms of receivables, while the amount of the impairment loss is posted as expense in “Other Expenses” account of the P&L. When a trade receivable is characterized as “not-to-be-collected” it is written off, using the account for provisions. In case where a receivable which was written off is subsequently collected, it is credited in the “Other Revenues” account of the P&L.

## **2.11 Cash and cash equivalents**

Cash and cash equivalents include cash in hand, sight deposits and time deposits of low risk.

## **2.12 Share capital**

Ordinary shares are classified as equity. Share capital represents the value of company’s shares in issue. Any excess of the fair value of the consideration received over the par value of the shares issued is recognized as “share premium” in shareholders equity.

Incremental costs directly attributable to the issue of new shares or options are shown in equity as a deduction, net of tax, from the proceeds. Expenses related to the issue of shares for acquisition of enterprises are included in cost of the enterprise that is acquired.

Where any Group company purchases the Company’s equity share capital (treasury shares), the consideration paid, including any directly attributable incremental costs, is deducted from equity attributable to the Company’s equity holders until the shares are cancelled, reissued or disposed off. Every gain or loss from sale of treasury shares net of other direct transaction expenses & taxes, if applicable, is shown as a reserve in equity.

## **2.13 Borrowings**

Borrowings are recognised at their value, reduced by any transaction costs. The fair value of the liability portion of a convertible bond is determined using a market interest rate for an equivalent non-convertible bond. This amount is recorded as a liability on an amortised cost basis until extinguished on conversion or maturity of the bonds.

## **2.14 Deferred income tax**

Current income tax is calculated using the financial statements of every company included in the consolidated financial statements, along with the applicable tax law. The income tax charge consists of the current income tax calculated upon the results of the Group companies, as they have been reformed in their taxation return applying the applicable tax rate.

Deferred income tax is determined using the liability method, on temporary differences arising between the tax bases of assets and liabilities and their carrying amounts.

Deferred income taxation is determined using tax rates that have been enacted on the balance sheet date and are expected to apply when the related deferred income tax asset is realised or the related deferred income tax liability is settled. Deferred tax is charged or credited in the income statement, except when it relates to items credited or charged directly to equity, in which case the deferred tax is also presented in equity.

Deferred income tax assets are recognised to the extent that is probable that future taxable profit will be available against which the temporary differences can be utilised.

## **2.15 Employee benefits**

### **Short-term benefits**

Short-term employee benefits towards the employees in money and in kind are recognised as an expense when accrued.

### **Pension obligations**

The liability recorded in the balance sheet in respect of defined benefit pension plans is the present value of the defined benefit obligation for the defined benefit less the fair value of the assets of the plan and the changes occurring from other actuarial gains or

losses and past service costs. The defined benefit obligation is calculated annually using the projected unit credit method. The present value of the defined benefit obligation is determined by discounting the estimated future cash outflows using interest rates of high-quality corporate bonds that are denominated, in the currency in which the benefits will be paid, and that have terms to maturity approximating to the terms of the related pension liability.

Past-service costs are recognised immediately in income, unless the changes to the pension plan are conditional on the employees remaining in service for a specified period of time (the vesting period). In this case, the past-service costs are amortised on a straight-line basis over the vesting period. Termination benefits are payable when employment is terminated before the normal retirement date. The Group recognises termination benefits when it is demonstrably committed. Benefits following due more than 12 months after the balance sheet date are discounted to present value.

## **2.16 Provisions**

Provisions are recognised when the Group has a present legal or constructive obligation as a result of past events, it is more likely than not that be required to settle the obligation.

## **2.17 Revenue recognition**

Revenue is measured at fair value of the sale of goods and services, net of value-added tax, rebates and discounts and after eliminating sales within the Group. Revenue is recognised as follows:

### **Sales of services**

Sales of services are recognised in the accounting period (invoices & with provision) in which the services are rendered.

### **Sales of goods**

Sales of goods are recognised when a Group entity has delivered products to the customer; the customer has accepted the products and the collection of the related receivables is reasonably assured.

**Interest income**

Interest income is recognised on a time-proportion basis using the effective interest method.

**Dividend income**

Dividend income is recognised when the right to receive payment is established.

**Income from rents**

Income from rents is recorded when accrued, according to the existing contracts.

**2.18 Leases**

Leases where the lessor retains substantially all the risks and rewards of ownership are classified as operating leases.

**Lessor**

Rental income is recognised on a straight-line basis over the lease term.

**Lessee**

Payments made under operating leases are charged to the income statement on a straight-line basis over the period of the lease.

**2.19 Dividend Distribution**

Dividend distribution is recognised as a liability in the fiscal period's financial statements in which the management's dividend policy is approved by the Ordinary Company's Shareholders Meeting.

**2.20 Government grants**

Government grants for training staff after they are certified and settled by the competent Government body (Ministry of Labour – OAED [Manpower, Employment Organisation]) are recognised in income (provision). Government grants received in respect of expenses are reflected in the income statement when the related expense is incurred so that the expense is matched to the income received. Government grants relating to assets are recognised in liabilities (current or non-current) as grants for PPE and are credited to the income statement according to the respective assets useful life.

### **3. Financial risk management**

#### **3.1 Fair value estimation**

The fair value of financial instruments traded in active capital markets (stock exchange) is based on quoted market prices at the annual balance sheet or the balance sheet of the period. The fair value of financial instruments that are not traded in an active market is determined at historical cost (acquisition cost) at the balance sheet date. The nominal value less estimated credit adjustment of trade receivables and payables are assumed to approximate their fair values.

#### **3.2 Financial Risk**

Financial risk management performs a very significant role within the group's total risk management policy. The Group's financial instruments consist mainly of deposits with banks, trade accounts receivable and payable, transactions with the subsidiaries, associates, equity investments, dividends payable and lease obligations. There are no loan liabilities in foreign currencies except euros therefore the Company is not exposed to foreign exchange risks. The interest rate risk exposure for bank liabilities and investments is continuously audited in budgetary base. The Group's income and operating cash flows are substantially independent of changes in market interest rates as the operating cash available for investment and the interest-bearing receivables mainly depend on Euro interest rates which have both historically low fluctuation and the future forecast market fluctuation remains especially low as well. Various scenarios are examined taking into consideration refinancing, renewal of existing positions, alternative financing and interest hedging. Regarding the proper management of the liquidity, this is done by combination of working capital and cash flows, approved bank credit and strict monitoring of cash flows. The Group has sufficient non used call/demand borrowing facilities that can be utilized to fund any potential shortfall in cash resources.

### **4. Critical accounting estimates and judgments**

Estimates and judgements are continually evaluated and are based on historical experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances.

#### **4.1 Critical accounting estimates and assumptions**

The Group makes estimates and assumptions concerning the future. The estimates and assumptions that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next financial year are discussed below:

##### **Income taxes**

The Group is subject to uniform income tax rate given that all Group companies activate in Greece. Where the final tax outcome of these matters is different from the amounts that were initially recorded, such differences will impact the income tax and deferred tax provisions in the period in which such determination is made.

##### **Litigious cases**

The Group, conducts estimations regarding the pending lawsuits and proceeds to provisions when it is believed that the Company's and the Group's accounting balances of fixed assets and liabilities will be substantially affected. The estimations are important but not restrictive. The actual future events may differ than the above estimations.

##### **Fair value and useful lives of Property, plant and equipment**

In addition, management makes estimations in relation to useful lives of amortized assets. Further information is given in paragraph 2.5.

##### **Estimated impairment of goodwill**

Group's management examines annually whether goodwill has suffered any impairment, in accordance with the accounting policy stated in Note 2.5.

#### **5. Information by Business Unit**

##### **Principal Information**

The following information refers to the business units of the Group's companies, which should be reported individually in the financial statements.

The business units have been defined based on the Group's companies structure considering also the fact that the decision-makers monitor their financial information individually, as presented by the company for each of its subsidiaries included in the consolidation.

Using the quantitative criteria set by the relevant IFR standard, IASO S.A. and its subsidiaries were set as business units that must be reported individually in the financial statements. The accounting principles are the same with the ones used at the Annual Financial Statements and consist of independent units – companies.

The Management evaluates the performance of these business units, based on the operating and the net profits, as well as the potential synergies between the business units and the complement of services in the whole spectrum of health services in the human life-cycle.

The parent company “IASO S.A” operates in the health care sector, covering all the obstetrics and gynecology cases and a broad range of diagnostic and therapeutic services. Its operations, in short, can be classified to inpatients cases (obstetrics and surgical) and outpatients cases (diagnostic laboratories and outpatients departments).

The subsidiary company “IASO GENERAL CLINIC OF HOLARGOS S.A.” operates also in the health care sector, as a general hospital, covering all surgical and non-surgical cases with the exception of the obstetrics and gynecology related cases. It also operates complete and fully organized diagnostic laboratories, outpatient departments and emergency units. Its operation can be classified to inpatient cases (surgical, non-surgical) that require hospitalization and outpatients cases (diagnostic laboratories, outpatient departments, etc) that do not require patient hospitalization.

The subsidiary company “MEDSTEM SERVICES S.A.” operates mainly in the healthcare supporting services, with its main objective, from 01/01/2006 being the processing and storage of infant stem cells. In addition to the aforementioned provision of health services, it also operates in parallel non-medical services that at the moment are not considered important due to their small contribution to the Group’s total revenue. These services where necessary will be mentioned totally as “Other services provided”.

The Group’s other subsidiaries are either in a construction stage or have not commenced productive activity yet and lack any revenues. However, due to the reconciliation of operating and net profits in a consolidated base they will be presented individually by the title “Other companies”.

**I. Total Comprehensive Income per Business Unit for the period 01/01-31/12/2009  
and 01/01-31/12/2008 respectively, are analysed as follows:**

01/01 – 31/12/2009	IASO S.A.	IASO GENERAL S.A.	MEDSTEM SERVICES S.A.	Other Companies	TOTAL	Intra-group eliminations	GROUP
Inpatients revenues	83.216.613,46	60.719.129,66	0,00	0,00	143.935.743,12		143.935.743,12
Inpatients number of cases	28.310	15.377					
Outpatients revenues	22.897.102,09	6.995.221,73	3.149.467,04	0,00	33.041.790,86		33.041.790,86
Outpatients number of cases	219.906	63.228					
Other revenues	2.290,83	6.018,54	0,00	0,00	8.309,37		8.309,37
Other services provided	0,00	0,00	1.513.783,73	0,00	1.513.783,73		1.513.783,73
Revenues from Group's customers	106.116.006,38	67.720.369,93	4.663.250,77	0,00	178.499.627,08		178.499.627,08
Inter-company sales	121.694,90	124.227,95	0,00	0,00	245.922,85	-245.922,85	0,00
Other operating revenues. expenses	155.989,25	-398.402,31	168.502,91	-927,63	-74.837,78	-185.874,15	-260.711,93
Operational expenses	-79.482.316,57	-65.940.788,60	-3.638.240,96	-1.050.721,19	-150.112.067,32	431.797,00	-149.680.270,32
Financial cost	-545.689,23	-928.454,08	4.592,50	291.203,16	-1.178.347,65	-765.000,00	-1.943.347,65
Earnings before taxes	26.365.684,73	576.952,89	1.198.105,22	-760.445,66	27.380.297,18	-765.000,00	26.615.297,18
Income taxes	-9.174.297,09	-3.628.548,62	-329.526,31	33.231,98	-13.099.140,05		-13.099.140,05
Net profit/loss for the period (A)	17.191.387,64	-3.051.595,73	868.578,91	-727.213,69	14.281.157,13	-765.000,00	13.516.157,13
Other comprehensive income after taxes (B)	0,00	0,00	0,00	0,00	0,00		0,00
Total comprehensive income after taxes (A)+(B)	17.191.387,64	-3.051.595,73	868.578,91	-727.213,69	14.281.157,13	-765.000,00	13.516.157,13

01/01 - 31/12/2008	IASO S.A.	IASO GENERAL S.A.	MEDSTEM SERVICES S.A.	Other Companies	TOTAL	Intra-group eliminations	GROUP
Inpatients revenues	84.784.578,09	63.789.058,47	0,00	0,00	148.573.636,56		148.573.636,56
Inpatients number of cases	28.381	15.954					
Outpatients revenues	24.118.945,76	6.656.551,63	3.632.399,45	0,00	34.407.896,84		34.407.896,84
Outpatients number of cases	227.262	57.513					
Other revenues	19.013,66	4.374,01	990.346,71	0,00	1.013.734,38		1.013.734,38
Other services provided	0,00	0,00		0,00	0,00		0,00
Revenues from Group's customers	108.922.537,51	70.449.984,11	4.622.746,16	0,00	183.995.267,78		183.995.267,78
Inter-company sales	129.342,92	173.508,18	16.133,97	0,00	318.985,07	-318.985,07	0,00
Other operating revenues. expenses	3.026.554,41	602.765,01	23.072,59	-940,96	3.651.451,05	-129.704,87	3.521.746,18
Operational expenses	-76.488.344,61	-66.182.357,65	-3.665.049,75	-465.769,59	-146.801.521,60	448.689,94	-146.352.831,66
Financial cost	-2.785.983,45	-2.203.925,69	73.066,59	-59.003,90	-4.975.846,45	-1.020.000,00	-5.995.846,45
Earnings before taxes	32.804.106,78	2.839.973,96	1.069.969,56	-525.714,45	36.188.335,85	-1.020.000,00	35.168.335,85
Income taxes	-7.930.905,60	-6.027.668,89	-335.694,60	-458.841,40	-14.753.110,49		-14.753.110,49
Net profit/loss for the period (A)	24.873.201,18	-3.187.694,93	734.274,96	-984.555,85	21.435.225,36	-1.020.000,00	20.415.225,36
Other comprehensive income after taxes (B)	-283.757,87	3.105.723,22	0,00	-761.037,22	2.060.928,13		2.060.928,13
Total comprehensive income after taxes (A)+(B)	24.589.443,31	-81.971,71	734.274,96	-1.745.593,07	23.496.153,49	-1.020.000,00	22.476.153,49

The statement of comprehensive income for the Company and the Group at 31/12/2009 and 31/12/2008 respectively does not include income and expenses that are included in

"IASO" PRIVATE GENERAL – OBSTETRIC – GYNECOLOGICAL & PAEDIATRICS CLINIC – DIAGNOSTIC - THERAPEUTIC & RESEARCH CENTER S.A.

'Other revenues' account as indicated by the revised IAS 1 or allowed by other IFRS, while the statement of comprehensive income of the Company and the Group at 31.12.2008 includes the amounts of €-283.757,87 and €2.060.928,13 respectively, which concern the revaluation of subsidiaries' property (Note 22 of Financial Statements).

**II. Assets' and Liabilities' allocation per Business Unit at 31/12/2009 and 31/12/2008 respectively is analysed as follows:**

01/01 – 31/12/2009	IASO S.A.	IASO GENERAL S.A.	MEDSTEM SERVICES S.A.	Other Companies	TOTAL	Intra-group eliminations	GROUP
<b>Assets per Business Unit</b>							
Operating assets per B. U.	147.722.902,96	99.093.220,74	2.376.008,98	0,00	<b>249.192.132,68</b>	-3.725.457,35	<b>245.466.675,33</b>
Non allocated assets per B.U.	148.569.693,77	12.010.202,57	5.408.889,13	108.868.325,23	<b>274.857.110,70</b>	-136.438.911,99	<b>138.418.198,71</b>
<b>Total</b>	<b>296.292.596,73</b>	<b>111.103.423,31</b>	<b>7.784.898,11</b>	<b>108.868.325,23</b>	<b>524.049.243,38</b>	<b>-140.164.369,34</b>	<b>383.884.874,04</b>
<b>Liabilities per Business Unit</b>							
Operating assets per B. U.	23.871.993,62	71.020.768,94	13.699.066,53	0,00	<b>108.591.829,09</b>	-3.725.457,35	<b>104.866.371,74</b>
Non allocated assets per B.U.	91.137.148,21	1.597.618,79	371.173,56	38.172.254,09	<b>131.278.194,65</b>	-4.469.116,59	<b>126.809.078,06</b>
<b>Total</b>	<b>115.009.141,83</b>	<b>72.618.387,73</b>	<b>14.070.240,09</b>	<b>38.172.254,09</b>	<b>239.870.023,74</b>	<b>-8.194.573,94</b>	<b>231.678.449,80</b>

01/01 – 31/12/2008	IASO S.A.	IASO GENERAL S.A.	MEDSTEM SERVICES S.A.	Other Companies	TOTAL	Intra-group eliminations	GROUP
<b>Assets per Business Unit</b>							
Operating assets per B. U.	141.146.212,36	100.442.574,50	2.165.122,16	0,00	<b>243.753.909,02</b>	-1.841.613,74	<b>241.912.295,28</b>
Non allocated assets per B.U.	141.615.934,56	9.485.518,60	4.595.676,54	78.330.340,48	<b>234.027.470,18</b>	-131.183.506,38	<b>102.843.963,80</b>
<b>Total</b>	<b>282.762.146,92</b>	<b>109.928.093,10</b>	<b>6.760.798,70</b>	<b>78.330.340,48</b>	<b>477.781.379,20</b>	<b>-133.025.120,12</b>	<b>344.756.259,08</b>
<b>Liabilities per Business Unit</b>							
Operating assets per B. U.	23.961.544,02	68.439.703,66	5.098.496,39	0,00	<b>97.499.744,07</b>	-1.841.613,74	<b>95.658.130,33</b>
Non allocated assets per B.U.	82.229.390,00	9.640,88	305.141,17	25.039.061,69	<b>107.583.233,74</b>	-3.331.278,71	<b>104.251.955,03</b>
<b>Total</b>	<b>106.190.934,02</b>	<b>68.449.344,54</b>	<b>5.403.637,56</b>	<b>25.039.061,69</b>	<b>205.082.977,81</b>	<b>-5.172.892,45</b>	<b>199.910.085,36</b>

## 6. Property, plant and equipment

### Property, plant and equipment of the Company at 31.12.2009

	Land & Buildings	Vehicles & Machinery	Other property, plant & equipment	Total
<b>1.1.2009</b>				
Cost or valuation	116.142.040,71	37.421.957,57	10.923.829,10	164.487.827,38
Accumulated depreciation	9.805.617,27	17.482.783,52	7.668.882,50	34.957.283,29
<b>Net book amount</b>	<b>106.336.423,44</b>	<b>19.939.174,05</b>	<b>3.254.946,60</b>	<b>129.530.544,09</b>
<b>Movement 01.01 - 31.12.2009</b>				
Opening net book amount	106.336.423,44	19.939.174,05	3.254.946,60	129.530.544,09
Revaluation surplus	0,00	0,00	0,00	0,00
Additions	3.438.586,68	4.677.329,80	1.419.294,10	9.535.210,58
Disposals	0,00	1.162.020,20	727,09	1.162.747,29
Writing-off of sold assets initial value	0,00	1.151.805,16	40,39	1.151.845,55
Writing-off of cumulative depreciation	1.878.528,31	2.437.686,66	645.512,35	4.961.727,32
<b>Net book amount</b>	<b>107.896.481,81</b>	<b>22.168.602,15</b>	<b>4.028.041,65</b>	<b>134.093.125,61</b>
<b>31.12.2009</b>				
Cost or valuation	119.580.627,39	40.937.267,17	12.342.396,11	172.860.290,67
Accumulated depreciation	11.684.145,58	18.768.665,02	8.314.354,46	38.767.165,06
<b>Net book amount</b>	<b>107.896.481,81</b>	<b>22.168.602,15</b>	<b>4.028.041,65</b>	<b>134.093.125,61</b>

### Property, plant and equipment of the Company at 31.12.2008

	Land & Buildings	Vehicles & Machinery	Other property, plant & equipment	Total
<b>1.1.2008</b>				
Cost or valuation	100.578.556,77	33.132.330,26	9.765.165,18	143.476.052,21
Accumulated depreciation	8.321.069,50	15.664.957,21	7.061.748,68	31.047.775,39
<b>Net book amount</b>	<b>92.257.487,27</b>	<b>17.467.373,05</b>	<b>2.703.416,50</b>	<b>112.428.276,82</b>
<b>Movement 01.01 - 31.12.2008</b>				
Opening net book amount	92.257.487,27	17.467.373,05	2.703.416,50	112.428.276,82
Revaluation surplus	9.926.808,77	0,00	0,00	9.926.808,77
Additions	5.636.675,17	4.300.540,62	1.163.640,26	11.100.856,05
Disposals	0,00	10.913,31	4.976,34	15.889,65
Writing-off of sold assets initial value	0,00	136,55	4.976,32	5.112,87
Writing-off of cumulative depreciation	1.484.547,77	1.817.962,86	612.110,14	3.914.620,77
<b>Net book amount</b>	<b>106.336.423,44</b>	<b>19.939.174,05</b>	<b>3.254.946,60</b>	<b>129.530.544,09</b>
<b>31.12.2008</b>				
Cost or valuation	116.142.040,71	37.421.957,57	10.923.829,10	164.487.827,38
Accumulated depreciation	9.805.617,27	17.482.783,52	7.668.882,50	34.957.283,29
<b>Net book amount</b>	<b>106.336.423,44</b>	<b>19.939.174,05</b>	<b>3.254.946,60</b>	<b>129.530.544,09</b>

## Property, plant and equipment of the Group at 31.12.2009

	Land & Buildings	Vehicles & Machinery	Other property, plant & equipment	Total
<b>1.1.2009</b>				
Cost or valuation	233.185.400,08	65.409.376,10	24.878.461,74	323.473.237,92
Accumulated depreciation	15.054.335,80	31.243.720,25	15.184.805,47	61.482.861,52
<b>Net book amount</b>	<b>218.131.064,28</b>	<b>34.165.655,85</b>	<b>9.693.656,27</b>	<b>261.990.376,40</b>
<b>Movement 01.01 - 31.12.2009</b>				
Opening net book amount	<b>218.131.064,28</b>	<b>34.165.655,85</b>	<b>9.693.656,27</b>	<b>261.990.376,40</b>
Revaluation surplus	0,00	0,00	0,00	0,00
Additions	33.576.128,07	5.364.777,16	1.657.209,11	40.598.114,34
Disposals	145.238,00	1.203.246,35	116.476,61	1.464.960,96
Writing-off of sold assets initial value	4.369,22	1.170.995,61	80.215,86	1.255.580,69
Writing-off of cumulative depreciation	2.663.353,07	4.681.019,94	1.279.861,65	8.624.234,66
<b>Net book amount</b>	<b>248.902.970,50</b>	<b>34.817.162,33</b>	<b>10.034.742,98</b>	<b>293.754.875,81</b>
<b>31.12.2009</b>				
Cost or valuation	266.616.290,15	69.570.906,91	26.419.194,24	362.606.391,30
Accumulated depreciation	17.713.319,65	34.753.744,58	16.384.451,26	68.851.515,49
<b>Net book amount</b>	<b>248.902.970,50</b>	<b>34.817.162,33</b>	<b>10.034.742,98</b>	<b>293.754.875,81</b>

## Property, plant and equipment of the Group at 31.12.2008

	Land & Buildings	Vehicles & Machinery	Other property, plant & equipment	Total
<b>1.1.2008</b>				
Cost or valuation	193.459.175,25	54.929.358,40	23.111.728,14	271.500.261,79
Accumulated depreciation	12.842.075,63	27.394.115,88	13.947.859,90	54.184.051,41
<b>Net book amount</b>	<b>180.617.099,62</b>	<b>27.535.242,52</b>	<b>9.163.868,24</b>	<b>217.316.210,38</b>
<b>Movement 01.01 - 31.12.2008</b>				
Opening net book amount	<b>180.617.099,62</b>	<b>27.535.242,52</b>	<b>9.163.868,24</b>	<b>217.316.210,38</b>
Revaluation surplus	17.604.051,49	0,00	0,00	17.604.051,49
Additions	22.122.173,34	10.666.410,52	1.786.748,51	34.575.332,37
Disposals	0,00	186.392,82	20.014,91	206.407,73
Writing-off of sold assets initial value	0,00	72.634,84	19.258,97	91.893,81
Writing-off of cumulative depreciation	2.212.260,17	3.922.239,21	1.256.204,54	7.390.703,92
<b>Net book amount</b>	<b>218.131.064,28</b>	<b>34.165.655,85</b>	<b>9.693.656,27</b>	<b>261.990.376,40</b>
<b>31.12.2008</b>				
Cost or valuation	233.185.400,08	65.409.376,10	24.878.461,74	323.473.237,92
Accumulated depreciation	15.054.335,80	31.243.720,25	15.184.805,47	61.482.861,52
<b>Net book amount</b>	<b>218.131.064,28</b>	<b>34.165.655,85</b>	<b>9.693.656,27</b>	<b>261.990.376,40</b>

The Group's land and buildings were last revaluated at 31/12/2008 by independent certified evaluators. Valuations were made on the basis of open market value. (More details in Note 29).

On the assets of the Company and the Group there are no real liens, apart from the subsidiary IASO GENERAL CLINIC OF HOLARGOS S.A. where there is a prenotation against its fixed assets amounted to € 54.000.000,00 in favor of the National Bank of Greece for securing debenture loan of € 45.000.000,00, whose unpaid balance at 31/12/2009 amounted to € 25.000.000,00.

The Parent company **IASO S.A.**, during the fiscal year 2009, invested in fixed assets the amount of approximately €9,54 mil., mainly as follows:

- The amount of € 3,44 mil. was invested in buildings mainly for the completion of IASO Children's hospital as well as for the reconstruction and expansion of existing operating units.
- The amount of €4,68 mil. was invested in biomedical equipment for the completion of operations of IASO Children's hospital.
- The amount of € 1,42 mil. was invested in hotel equipment for the completion of operations of IASO Children's hospital.

At **IASO Thessalias S.A.** the investments of the fiscal year 2009 amounted approximately to €29,52 mil., regarding the completion of the buildings construction, where the company's clinic will operate along with the purchase of medical, nursing and hotel equipment.

At **IASO General S.A.**, during the fiscal year 2009, were invested €1,35 mil in the buildings reconstruction and also in the purchase of biomedical equipment for the operation of existing units.

At the subsidiary **MEDSTEM Services S.A.**, during the fiscal year 2009, were invested € 0,19 mil.

The aforementioned Group investments reached the total amount of € 40,60 mil. illustrating the Group's policy to create increased value for its shareholders by further development of the Group's competitive strengths and continuous upgrade of the offered services.

## 7. Intangible assets

### Intangible assets of the Company at 31.12.2009

	Trademarks & Licenses	Other	Total
<b>1.1.2009</b>			
Cost	139.286,87	2.404.909,32	2.544.196,19
Accumulated depreciation and impairment	28.841,35	1.502.685,39	1.531.526,74
<b>Net book amount 31.12.2008</b>	<b>110.445,52</b>	<b>902.223,93</b>	<b>1.012.669,45</b>
<b>Movement 01.01 - 31.12.2009</b>			
Opening net book amount	<b>110.445,52</b>	<b>902.223,93</b>	<b>1.012.669,45</b>
Additions	0,00	286.252,14	286.252,14
Writing-off of sold assets initial value	0,00	0,00	0,00
Writing-off of cumulative depreciation	0,00	0,00	0,00
Depreciation charge	11.089,86	174.483,77	185.573,63
<b>Net book amount</b>	<b>99.355,66</b>	<b>1.013.992,30</b>	<b>1.113.347,96</b>
<b>31.12.2009</b>			
Cost	139.286,87	2.691.161,46	2.830.448,33
Accumulated amortization and impairment	39.931,21	1.677.169,16	1.717.100,37
<b>Net book amount</b>	<b>99.355,66</b>	<b>1.013.992,30</b>	<b>1.113.347,96</b>

### Intangible assets of the Company at 31.12.2008

	Trademarks & Licenses	Other	Total
<b>1.1.2008</b>			
Cost	139.286,87	2.052.349,54	2.191.636,41
Accumulated depreciation and impairment	25.990,01	1.282.032,41	1.308.022,42
<b>Net book amount 31.12.2006</b>	<b>113.296,86</b>	<b>770.317,13</b>	<b>883.613,99</b>
<b>Movement 01.01 - 31.12.2008</b>			
Opening net book amount	<b>113.296,86</b>	<b>770.317,13</b>	<b>883.613,99</b>
Additions	0,00	352.559,78	352.559,78
Writing-off of sold assets initial value	0,00	0,00	0,00
Writing-off of cumulative depreciation	0,00	0,00	0,00
Depreciation charge	2.851,34	220.652,98	223.504,32
<b>Net book amount</b>	<b>110.445,52</b>	<b>902.223,93</b>	<b>1.012.669,45</b>
<b>31.12.2008</b>			
Cost	139.286,87	2.404.909,32	2.544.196,19
Accumulated amortization and impairment	28.841,35	1.502.685,39	1.531.526,74
<b>Net book amount</b>	<b>110.445,52</b>	<b>902.223,93</b>	<b>1.012.669,45</b>

## Intangible assets of the Group at 31.12.2009

	Trademarks & Licenses	Other	Total
<b>1.1.2009</b>			
Cost	139.286,87	4.682.900,37	4.822.187,24
Accumulated depreciation and impairment	28.841,35	3.236.499,54	3.265.340,89
<b>Net book amount 31.12.2008</b>	<b>110.445,52</b>	<b>1.446.400,83</b>	<b>1.556.846,35</b>
<b>Movement 01.01 - 31.12.2009</b>			
Opening net book amount	<b>110.445,52</b>	<b>1.446.400,83</b>	<b>1.556.846,35</b>
Additions	0,00	331.782,15	331.782,15
Writing-off of sold assets initial value	0,00	813,50	813,50
Writing-off of cumulative depreciation	0,00	527,44	527,44
Depreciation charge	2.851,34	329.120,23	331.971,57
<b>Net book amount</b>	<b>107.594,18</b>	<b>1.448.776,69</b>	<b>1.556.370,87</b>
<b>31.12.2009</b>			
Cost	139.286,87	5.013.869,02	5.153.155,89
Accumulated amortization and impairment	31.692,69	3.565.092,33	3.596.785,02
<b>Net book amount</b>	<b>107.594,18</b>	<b>1.448.776,69</b>	<b>1.556.370,87</b>

## Intangible assets of the Group at 31.12.2008

	Trademarks & Licenses	Other	Total
<b>1.1.2008</b>			
Cost	139.286,87	4.194.251,29	4.333.538,16
Accumulated depreciation and impairment	25.990,01	2.887.103,12	2.913.093,13
<b>Net book amount 31.12.2006</b>	<b>113.296,86</b>	<b>1.307.148,17</b>	<b>1.420.445,03</b>
<b>Movement 01.01 - 31.12.2008</b>			
Opening net book amount	113.296,86	1.307.148,17	1.420.445,03
Additions	0,00	488.649,08	488.649,08
Writing-off of sold assets initial value	0,00	0,00	0,00
Writing-off of cumulative depreciation	0,00	0,00	0,00
Depreciation charge	2.851,34	349.396,42	352.247,76
<b>Net book amount</b>	<b>110.445,52</b>	<b>1.446.400,83</b>	<b>1.556.846,35</b>
<b>31.12.2008</b>			
Cost	139.286,87	4.682.900,37	4.822.187,24
Accumulated amortization and impairment	28.841,35	3.236.499,54	3.265.340,89
<b>Net book amount</b>	<b>110.445,52</b>	<b>1.446.400,83</b>	<b>1.556.846,35</b>

Other intangible assets exclusively concern software applications of the Company like the accounting data management system, the personnel management system as well as the medical services costing management application. The estimated life cycle of the

above intangible assets is demonstrated in chapter 2.6 and they are amortised annually. The management re-exams their values at reasonable periods and any adjustments will respectively increase or decrease their present value.

## **8. Transactions with related parties**

The participations, inter-company transactions, balances and income and expenses are eliminated upon consolidation.

### **8.1 Inter-company transactions**

Inter-company income and expenses of the Group's companies for the period 01.01-31.12.2009:

<b>IASO S.A. SALES TO RELATED PARTIES</b>						
	<b>FY 2009</b>			<b>FY 2008</b>		
<b>DESCRIPTION</b>	<b>IASO GENERAL</b>	<b>MEDSTEM</b>	<b>TOTAL</b>	<b>IASO GENERAL</b>	<b>MEDSTEM</b>	<b>TOTAL</b>
Sales of Consumables	3.025,84	15.936,63	<b>18.962,47</b>	3.624,92	14.533,97	<b>18.158,89</b>
Other services	0,00	701,43	<b>701,43</b>	0,00	818,10	<b>818,10</b>
Revenues from services provision	102.031,00	0,00	<b>102.031,00</b>	125.718,00	0,00	<b>125.718,00</b>
Rents and tenancy joint expenses	0,00	131.430,15	<b>131.430,15</b>	0,00	128.886,77	<b>128.886,77</b>
<b>TOTAL</b>	<b>105.056,84</b>	<b>148.068,21</b>	<b>253.125,05</b>	<b>129.342,92</b>	<b>144.238,84</b>	<b>273.581,76</b>

<b>IASO S.A. PURCHASES FROM RELATED PARTIES</b>						
	<b>FY 2009</b>			<b>FY 2008</b>		
<b>DESCRIPTION</b>	<b>IASO GENERAL</b>	<b>MEDSTEM</b>	<b>TOTAL</b>	<b>IASO GENERAL</b>	<b>MEDSTEM</b>	<b>TOTAL</b>
Outsourced processed services	115.183,00	0,00	<b>115.183,00</b>	169.661,06	0,00	<b>169.661,06</b>
Medical supplies	6.426,43	0,00	<b>6.426,43</b>	3.847,12	0,00	<b>3.847,12</b>
Rents and tenancy joint expenses	54.444,00	0,00	<b>54.444,00</b>	0,00	0,00	<b>0,00</b>
Consumables	2.618,52	0,00	<b>2.618,52</b>	0,00	1.600,00	<b>1.600,00</b>
<b>TOTAL</b>	<b>178.671,95</b>	<b>0,00</b>	<b>178.671,95</b>	<b>173.508,18</b>	<b>1.600,00</b>	<b>175.108,18</b>

<b>SUBSIDIARIES' DIVIDENDS COLLECTED</b>	
<b>SUBSIDIARY</b>	<b>DIVIDEND</b>
MEDSTEM SERVICES S.A.	765.000,00

On 18.06.2009, the Shareholders' General Meeting of the subsidiary MEDSTEM SERVICES S.A. decided a dividend distribution of total amount €765.000,00 or €75,00/Share. The above dividend was collected by the parent company (€757.350,00) and the subsidiary IASO General S.A. (€7.650,00). The transaction at Group level has been eliminated.

<b>FEES OF DIRECTORS AND MEMBERS OF THE B.O.D. BASED ON IAS 24</b>		
	<b>Group</b>	<b>Company</b>
Directors' Fees (1)	1.101.064,36	1.101.064,36
Members of BoD Fees (2)	669.455,00	661.430,00
<b>Total</b>	<b>1.770.519,36</b>	<b>1.762.494,36</b>

1. The Directors' fees include wages, employers' social security contributions, other fees, extraordinary fees, bonuses, firing compensations and other fringe benefits.
2. There is no remuneration for the BoD Members regarding their capacity as Members of the BoD. The aforementioned fees refer exclusively to payments for the provision of health care services to the Company or the Group under the professional capacity as medical doctors as self-employed professionals.

*In the Financial Statements, that are published according to the Hellenic Capital Market Committee's relevant decision as well as article 135 L.2190/1920, BoD's fees (case 2) have been included in "Purchases of Consumables and Services" of the additional data in the published Condensed Financial Data and Information of the Group and the Company.*

<b>RECEIVABLES AND LIABILITIES OF RELATED PARTIES AT 31/12/2009</b>					
<b>LIABILITIES</b>	<b>RECEIVABLES</b>				
	<b>IASO S.A.</b>	<b>MODERN MULTIFUNCTIONAL CENTER S.A.</b>	<b>IASO GENERAL S.A.</b>	<b>MEDSTEM SERVICES S.A.</b>	<b>Total</b>
<b>IASO S.A.</b>	-	-	158.366,16	-	<b>158.366,16</b>
<b>MEDSTEM SERVICES S.A.</b>	10.477,04	-	-	-	<b>10.477,04</b>
<b>IASO GENERAL S.A.</b>	237.832,64	-	-	-	<b>237.832,64</b>
<b>TOTAL</b>	<b>248.309,68</b>	-	<b>158.366,16</b>	-	<b>406.675,84</b>

<b>RECEIVABLES AND LIABILITIES OF RELATED PARTIES AT 31/12/2008</b>					
	<b>RECEIVABLES</b>				
<b>LIABILITIES</b>	<b>IASO S.A.</b>	<b>MODERN MULTIFUNCTIONAL CENTER S.A.</b>	<b>IASO GENERAL S.A.</b>	<b>MEDSTEM SERVICES S.A.</b>	<b>Total</b>
<b>IASO S.A.</b>	-	-	497.716,24	-	<b>497.716,24</b>
<b>MEDSTEM SERVICES S.A.</b>	5.869,13	-	-	-	<b>5.869,13</b>
<b>IASO GENERAL S.A.</b>	669.305,08	-	-	-	<b>669.305,08</b>
<b>TOTAL</b>	<b>675.174,21</b>	-	<b>497.716,24</b>	<b>18.654,23</b>	<b>1.172.890,45</b>

The inter-company and intra group income and expenses, the receivables and liabilities as well as the fees of Directors and the Members of the BoD constitute transactions with related parties according to IAS 24.

## **8.2 Investments to subsidiaries**

Parent Company's as well as subsidiaries' participations in other Group's non-listed companies were evaluated by the method of "acquisition value", which is the method that will always be used by the Group. Subsidiaries' financial statements are prepared according to the Group's accounting principles. The initial goodwill (initial consolidation adjustment) has been reflected in the consolidated profit and loss statements.

<b>INVESTMENTS TO SUBSIDIARIES AT 31/12/2009</b>	<b>% OF PARTICIPATION</b>	<b>PARENT COMPANY'S PARTICIPATION</b>	<b>EQUITY 31.12.2009</b>	<b>MINORITY INTERESTS</b>
1. IASO GENERAL CLINIC OF HOLARGOS S.A.	97,07%	98.013.771,50	38.427.152,83	1.126.377,75
2. IASO MACEDONIAS HEALTH GROUP OF NORTHERN GREECE S.A.	100,00%	6.717.159,86	21.292.538,88	0,00
3. IASO OF SOUTHERN SUBURBS GENERAL CLINIC-PRIVATE OBSTETRICS S.A.	53,43%	3.374.400,00	10.619.111,00	4.945.381,22
4. MODERN MULTIFUNCTIONAL REHABILITATION-RESTORATION CENTER S.A.	99,97%	4.861.890,00	5.023.158,80	1.462,44
5. IASO HEALTH ENTERPRISES S.A.	99,97%	297.000,00	312.042,59	93,61
6. MEDSTEM SERVICES S.A.	99,97%	475.200,00	1.460.740,05	429,63
7. IASO THESSALIAS GENERAL CLINIC-PRIVATE OBSTETRICS S.A.	75,65%	15.313.813,50	28.831.934,10	7.021.158,54
<b>TOTAL</b>		<b>129.053.234,86</b>	<b>105.966.678,25</b>	<b>13.094.903,19</b>

INVESTMENTS TO SUBSIDIARIES AT 31/12/2008	% OF PARTICIPATION	PARENT COMPANY'S PARTICIPATION	EQUITY 31.12.2008	MINORITY INTERESTS
1. IASO GENERAL CLINIC OF HOLARGOS S.A.	97,07%	98.013.771,50	41.478.748,56	1.215.826,21
2. IASO MACEDONIAS HEALTH GROUP OF NORTHERN GREECE S.A.	100,00%	6.717.159,86	21.301.611,11	0,00
3. IASO OF SOUTHERN SUBURBS GENERAL CLINIC-PRIVATE OBSTETRICS S.A.	53,43%	3.374.400,00	10.452.854,27	4.867.954,50
4. MODERN MULTIFUNCTIONAL REHABILITATION-RESTORATION CENTER S.A.	99,97%	4.861.890,00	5.043.408,24	1.468,33
5. IASO HEALTH ENTERPRISES S.A.	99,97%	297.000,00	316.540,58	94,96
6. MEDSTEM SERVICES S.A.	99,97%	475.200,00	1.357.161,14	399,17
7. IASO THESSALIAS GENERAL CLINIC-PRIVATE OBSTETRICS S.A.	67,93%	8.246.309,00	11.578.265,85	3.713.238,15
<b>TOTAL</b>		<b>121.985.730,36</b>	<b>91.528.589,75</b>	<b>9.798.981,32</b>

In addition:

1) On 03/03/2009, the share capital increase, through cash payment with preemption rights in favor of the existing shareholders, of the subsidiary company "IASO THESSALIAS S.A." was completed. The aforementioned share capital increase was decided on 01/11/2008 by the Extraordinary Shareholders Meeting of the company and took place from 01/11/2008 until 03/03/2009. It was covered by 44,22% by the deposit of € 3.758.779,50, which corresponds to 1.073.937 new common registered shares with voting rights, while 1.354.635 shares were left indisposed.

Upon resolution of the Board of Directors dated 03/03/2009, the indisposed shares (1.354.635) were disposed by their judgment to new shareholders that were interested in participating and deposited the relevant amounts along with the existing shareholders that chose to participate beyond their preemption right and deposited the relevant amounts. As a result the total coverage of the share capital increase was 100% and amounted to €8.500.002,00. Following that, the share capital of the company increased by €4.857.144,00 through the issuance of 2.428.572 new common registered shares with voting rights, of nominal value € 2,00 per share. The par value of the shares issued, amounting € 3.642.858, is recognized as "share premium" in shareholders equity. (G.G. 2554/07.04.09). In the aforementioned share capital increase and for the period 01/01/2009-31/12/2009, the parent company participated with the amount of € 1,00 (€2.500.000,00 was the participation of the parent company during the fiscal year 2008) while the Company's subsidiaries IASO GENERAL S.A. and Medstem Services S.A. participated with the amount of €2.000.001,50 and € 727.321,00 respectively.

"IASO" PRIVATE GENERAL – OBSTETRIC – GYNECOLOGICAL & PAEDIATRICS CLINIC – DIAGNOSTIC - THERAPEUTIC & RESEARCH CENTER S.A.

2) Upon resolution of the Extraordinary Meeting of shareholders of the subsidiary company “IASO THESSALIAS S.A.” held on 04.04.2009, it was decided to increase the share capital by € 5.493.324,00 in cash, through the issuance of 2.746.662 new registered shares of nominal value € 2,00 each and issue price € 3,50. The arising Share Premium Reserve amounted to € 4.119.993,00 (1799/06.05.2009 Decision of Larissa Prefecture). In the aforementioned share capital increase and for the period 01/01/2009-31/12/2009, the Company’s subsidiary IASO GENERAL S.A. participated by the amount of €4.000.003,00.

3) Upon resolution of the General Meeting of shareholders of the subsidiary company "IASO OF SOUTHERN SUBURBS S.A.", held on 15.06.2009, it was decided to decrease the nominal value of shares from €5,00 to €2,50 with a simultaneous issuance, due to this decrease, of 2.012.000 new common blocked registered shares (split 2/1), of nominal value €2,50 each and as a result the total number of shares increased from 2.012.000 common blocked registered shares to 4.024.000 common registered shares with voting rights of €2,50 each.

## **9. Available-for-sale financial assets**

Available-for-sale financial assets include the following:

	<b>Group 31.12.2008</b>	<b>Group 31.12.2009</b>	<b>Company 31.12.2008</b>	<b>Company 31.12.2009</b>
<b>Listed securities:</b>	None	None	None	None
<b>Unlisted securities:</b>				
Shares	4.189.927,64	4.189.927,64	4.189.927,64	4.189.927,64
<b>Total</b>	<b>4.189.927,64</b>	<b>4.189.927,64</b>	<b>4.189.927,64</b>	<b>4.189.927,64</b>

The available-for-sale financial assets consist of portfolio investments in companies not listed in organized stock markets.

## **10. Other financial assets at fair value through income statement**

	<b>Group 31.12.2008</b>	<b>Group 31.12.2009</b>	<b>Company 31.12.2008</b>	<b>Company 31.12.2009</b>
<b>Listed securities:</b>				
Mutual Funds	363.916,07	451.485,51	363.916,07	451.485,51
<b>Unlisted securities:</b>	None	None	None	None
<b>Total</b>	<b>363.916,07</b>	<b>451.485,51</b>	<b>363.916,07</b>	<b>451.485,51</b>

The mutual funds were marked to market on 31.12.2009 according to the price announced by the Fund Management Company.

## **11. Trade and other receivables**

	<b>Group 31.12.2008</b>	<b>Group 31.12.2009</b>	<b>Company 31.12.2008</b>	<b>Company 31.12.2009</b>
Customers	27.278.559,00	31.129.277,24	2.869.321,92	3.351.953,92
Notes receivable on hand	7.307.069,08	8.444.347,85	1.828.921,55	2.231.696,20
Notes overdue	2.593.178,86	3.248.397,16	1.008.705,01	1.345.759,71
Cheques receivables	2.305.913,14	1.505.741,86	806.000,35	750.958,75
Cheques receivables overdue	255.957,14	296.219,18	97.868,77	131.230,81
Doubtful customers	2.567.158,70	2.648.672,50	2.098.775,95	2.180.289,75
<b>Less:</b> Provision for impairment of receivables	-7.441.636,36	-8.536.378,01	-3.335.563,74	-3.425.305,39
<b>Total Receivables</b>	<b>34.866.199,56</b>	<b>38.736.277,78</b>	<b>5.374.029,81</b>	<b>6.566.583,75</b>
Miscellaneous debtors	11.252.311,22	16.125.631,12	10.761.787,61	11.051.809,30
Down payments for purchases	78.993,25	365.047,06	77.413,24	195.926,05
Debit transit accounts	599.375,05	1.969.135,91	454.794,08	683.177,33
Other	224.079,51	230.601,94	24.842,15	27.942,15
<b>Total Other Receivables</b>	<b>12.154.759,03</b>	<b>18.690.416,03</b>	<b>11.318.837,08</b>	<b>11.958.854,83</b>

All the above receivables are short-term and there is no need to discount them at the date of the balance sheet. The bad debt provision includes specific bad debt provision for all receivables from customers that are considered as doubtful.

Group's "Other Receivables" account and more specifically "Miscellaneous debtors" account, includes the amount of € 2.500.000,00, which concerns a prepayment of the subsidiary company IASO of Southern Suburbs, for the purchase of a piece of land, based

on a preliminary contract. The size of the plot of land is 12.680 m<sup>2</sup> and it is located at the municipality of Agios Ioannis Redis. The land belongs to INTRAKAT S.A.

## **12. Inventories**

	<b>Group 31.12.2008</b>	<b>Group 31.12.2009</b>	<b>Company 31.12.2008</b>	<b>Company 31.12.2009</b>
Consumables	5.279.129,64	5.317.574,71	2.753.862,66	2.357.564,88
Merchandise	186.451,74	121.326,72	0,00	0,00
<b>Total</b>	<b>5.465.581,38</b>	<b>5.438.901,43</b>	<b>2.753.862,66</b>	<b>2.357.564,88</b>

The inventories level is considered by the Management as sufficient for securing smooth and uninterrupted operations. The distribution of the “Cost of services”, “Cost of sales” and “Administrative expenses” is presented in Note 22. The Company and the Group take all the necessary measures (insurance, safekeeping) so as to minimize the risk and contingent damages due to physical disasters, thefts etc.

## **13. Cash and cash equivalents**

	<b>Group 31.12.2008</b>	<b>Group 31.12.2009</b>	<b>Company 31.12.2008</b>	<b>Company 31.12.2009</b>
Cash on hand	102.684,70	79.028,23	48.534,37	61.217,10
Sight deposits	8.729.570,33	8.685.771,95	2.809.163,38	2.767.170,58
Time deposits	14.530.636,27	11.399.999,97	3.299.999,97	3.599.999,97
<b>Total</b>	<b>23.362.891,30</b>	<b>20.164.800,15</b>	<b>6.157.697,72</b>	<b>6.428.387,65</b>

## **14. Borrowings**

Borrowings are recognised at actual value decreased by any direct costs for the realisation of the transaction. The analysis of the Company’s and the Group’s borrowings with current and non-current maturities per company at 31.12.2009 is the following:

	<b><u>Current</u></b>	<b><u>Non-current</u></b>	<b><u>Total</u></b>
IASO S.A.	5.500.000,00	69.750.000,00	72.250.000,00
IASO GENERAL S.A.	14.900.000,00	32.100.000,00	37.000.000,00
IASO THESSALIAS S.A.	2.000.000,00	30.000.000,00	32.000.000,00
<b>Total</b>	<b>22.400.000,00</b>	<b>121.850.000,00</b>	<b>144.250.000,00</b>

The analysis of the Company's and the Group's borrowings with current and non-current maturities per company at 31.12.2008 is the following:

	<u>Current</u>	<u>Non-current</u>	<u>Total</u>
IASO S.A.	5.500.000,00	66.750.000,00	72.250.000,00
IASO GENERAL S.A.	2.500.000,00	33.000.000,00	35.500.000,00
MEDSTEM SERVICES S.A.	0,00	14.500.000,00	14.500.000,00
<b>Total</b>	<b>8.000.000,00</b>	<b>114.250.000,00</b>	<b>122.250.000,00</b>

It must be noted that the matured debenture loan payments of the Group, for which there is an obligation of repayment within the current fiscal year, are not included in the Company's and the Group's long-term borrowings but are transferred to the short-term bank liabilities payable within the next fiscal year.

Long-term borrowings include the following loans that were raised during the fiscal year 2008:

- The parent company IASO S.A., on 07.11.2008, proceeded in signing a contract for the issuance of a common bond loan (revolving) up to the total amount of € 18.500.000,00. The loan has three year duration with an extension option of one plus one year. The loan will be used to finance IASO's investment and other needs which are in progress. National Bank of Greece S.A. and National Bank of Greece (Cyprus) LTD underwrote the coverage of the loan. The amount that has been drawn down until 31.12.2009 is €18.500.000 with expiration date 07/11/2011.
- The subsidiary company "IASO THESSALIAS S.A." proceeded on 15.02.2008, in signing a contract for the issuance of a common bond loan up to the total amount of € 33.000.000,00 with the National Bank of Greece as the organizer and bondholder representative. The loan has eight year duration. The loan will be used to partially finance the construction of the buildings, the purchase of mechanical, biomedical and hotel equipment for the clinic's operation.

The amount that has been drawn down until 31.12.2009, through the issuance of seven bond series, is € 30.000.000,00 and is analyzed as follows:

A' bond series, 15/02/2008, € 7.000.000,00

B' bond series, 21/05/2008, € 3.000.000,00

C' bond series, 07/11/2008, € 4.500.000,00

"IASO" PRIVATE GENERAL – OBSTETRIC – GYNECOLOGICAL & PAEDIATRICS CLINIC – DIAGNOSTIC - THERAPEUTIC & RESEARCH CENTER S.A.

D' bond series, 29/04/2009, € 2.500.000,00

E' bond series, 24/06/2009, € 6.500.000,00

F' bond series, 30/11/2009, € 3.000.000,00

The first installment, including the capitalized interests, is payable on 15/02/2011 and the last one (eleventh) is payable on 15/02/2016.

The long-term balance of the debenture loans raised by the Company and the Group will be repaid through the fiscal years as follows:

	<b>Group 31.12.2009</b>	<b>Company 31.12.2009</b>
Fiscal year 2010	22.400.000,00	5.500.000,00
Fiscal year 2011	30.500.000,00	24.000.000,00
Fiscal year 2012	27.100.000,00	5.500.000,00
Fiscal year 2013	8.500.000,00	5.500.000,00
Fiscal year 2014	37.750.000,00	34.750.000,00
Fiscal year 2015	3.000.000,00	0,00
Fiscal year 2016	15.000.000,00	0,00
<b>Total</b>	<b>144.250.000,00</b>	<b>75.250.000,00</b>

#### **14.1 Net borrowings**

	<b>Group 31.12.2009</b>	<b>Group 31.12.2008</b>	<b>Company 31.12.2009</b>	<b>Company 31.12.2008</b>
Total borrowings	144.250.000,00	122.250.000,00	75.250.000,00	72.250.000,00
Cash and cash equivalents	-20.164.800,15	-23.362.891,30	-6.428.387,65	-6.157.697,72
<b>Net borrowings</b>	<b>124.085.199,85</b>	<b>98.887.108,70</b>	<b>68.821.612,35</b>	<b>66.092.302,28</b>

The total amount of new borrowings comes mainly from the subsidiary IASO THESSALIAS S.A., and was used to finance the completion of the new General Clinic in Thessaly, which will commence its operation during 2010.

## **15. Trade and other payables**

	<b>Group 31.12.2008</b>	<b>Group 31.12.2009</b>	<b>Company 31.12.2008</b>	<b>Company 31.12.2009</b>
Suppliers	40.943.520,31	42.053.458,67	9.761.243,49	9.304.111,24
Insurance and pension fund dues	3.021.358,95	3.123.708,39	1.978.078,52	2.020.345,55
Tax liabilities	2.131.609,78	1.966.406,82	1.447.447,51	1.225.176,30
Sundry creditors	2.719.572,93	8.355.734,48	5.906.926,86	6.121.537,04
Transit credit balances	3.176.922,95	3.225.681,81	1.790.480,12	1.923.712,23
Other liabilities	6.026.829,39	76.010,44	53.310,62	66.010,44
<b>Total</b>	<b>58.019.814,31</b>	<b>58.801.000,61</b>	<b>20.937.487,12</b>	<b>20.660.892,80</b>

There are third party lawsuits for indemnities against the Company, the Company and associated physicians as well as the Group's companies, for initial claims amounting to approximately € 107,72 mil. and € 115,84 mil respectively. These cases according to the Group's legal department are covered almost in full by insurance contracts for professional liability and as a result, in case that some of them do not favour the company, they will be covered by the insurance companies. Besides the aforementioned insurance coverage, the Company's Management, on 31/12/2009, proceeded for the first time through its P&L statement, to a cumulative provision for potential loss, which may occur beyond the insurance coverage, amounting to €4,35 mil. and €5,18 mil. for the Company and the Group respectively. These amounts are significantly raised due to the revocation of the operating license of the insurance company "ASPIS", against which, the Group companies have proceeded in adduction.

The aforementioned lawsuits are analysed as follows:

### **a. Lawsuits regarding medical malpractice**

There are third party lawsuits of patients and or their inheritors against the associated physicians as well as the Group's companies (IASO S.A. and IASO GENERAL S.A.) as indemnity and/or monetary compensation for moral injury, due to alleged medical "malpractice" for a total amount of approximately € 114,43 mil.

The outcome of these lawsuits is estimated not to have a material effect on the financial status of the Group's companies, since the claimed compensations are considered as extremely exaggerated and are not going to be awarded by the Greek courts, based on the heard law-cases. In case, where some of the lawsuits end up with a winning verdict, then

they will be covered, totally or in large part, by the insurance companies, with which malpractice contracts have been signed, either by the Group's companies or the associated physicians. Besides the aforementioned insurance coverage the Company and the Group have made a provision for potential loss of approximately €4,00 mil and €4,42 mil respectively.

**b. Other lawsuits**

In addition to the aforementioned cases, there are third party lawsuits against the Group's companies (labour differences e.t.c.) for a total amount of approximately € 1,41 mil, the outcome of these cases is estimated not to have a material effect on the financial status of the Company and the Group, respectively. In this regard, the Company and the Group have made a provision for potential loss of approximately € 0,35 mil. and € 0,76 respectively.

**16. Retirement benefit obligations**

Regarding the retirement benefit obligations, an actuarial calculation has been prepared, according to IAS 19, applying the method mentioned in § 2.15. From the said calculation arose accumulatively the following balances per company.

COMPANY	PERIOD					
	31.12.2004	31.12.2005	31.12.2006	31.12.2007	31.12.2008	31.12.2009
IASO S.A.	1.596.685,53	1.873.325,56	2.271.636,74	2.585.827,87	3.024.056,90	3.211.100,82
IASO GENERAL S.A.	994.805,66	1.167.147,46	1.514.068,82	1.518.801,13	1.709.630,45	1.816.883,43
MEDSTEM SERVICES S.A.	2.158,80	6.725,07	15.694,81	15.745,35	23.412,74	21.148,63
IASO THESSALIAS S.A.	4.754,63	3.922,18	3.922,18	3.922,18	3.922,18	13.631,10
<b>GROUP</b>	<b>2.598.404,62</b>	<b>3.051.120,27</b>	<b>3.805.322,55</b>	<b>4.124.296,53</b>	<b>4.761.022,27</b>	<b>5.062.763,98</b>

Due to the revision of the average annual increase of employees' wages for the remaining labour life from 5,5% to 5,0%, the total amount of the actuarial calculation amounts to €5.062.763,98 for the Group and €3.211.100,82 for the Company in respect. As a result the burden has been decreased by €301.741,71 for the Group and €187.043,92 for the Company, in respect. The basic actuarial assumptions adopted by all the Group's Companies that employ personnel are the following:

<b>Assumptions</b>	<b>Group</b>	<b>Company</b>
Discount rate (*)	From 2,75 until 6,00	From 2,75 until 6,00
Anticipated annual average increase of wages	5,00%	5,00%
Personnel's remaining labour life (**)	Depending on each employee	Depending on each employee

(\*) The discount rate used, according to IAS 19, for the calculation of present values and pension payments, was determined based on the Greek state's bonds rates, which vary between 2,75% and 6,00% depending on the length of their expiry date. The discount rate reflects the estimated time for paying the benefits.

(\*\*) The remaining labour life of personnel is calculated based on the declared labor life of each employee and their retirement standards, which are defined to 65 years of age for men and 60 years of age for women.

### **17. Other operating income (gains)**

	<b>Group 31.12.2008</b>	<b>Group 31.12.2009</b>	<b>Company 31.12.2008</b>	<b>Company 31.12.2009</b>
- Income from rentals	2.230.456,56	2.328.241,91	1.136.633,73	1.201.798,07
- Grants	193.980,87	337.465,52	84.232,42	194.096,28
- Income from side business	1.604.675,81	2.137.983,60	1.578.816,22	2.137.983,60
- Other customer revenues and non-current assets gains	88.234,62	66.155,56	84.256,22	62.100,84
- Extraordinary income / expenses	137.237,26	378.823,46	137.100,26	285.571,27
- Income from unused prior periods provisions	0,00	35.004,39	0,00	0,00
-Income from property revaluation	0,00	930.000,00	0,00	630.000,00
- Other	30.345,80	27.757,72	36.780,02	35.296,95
<b>Total</b>	<b>4.284.930,92</b>	<b>6.241.432,16</b>	<b>3.057.818,87</b>	<b>4.546.847,01</b>

During the year 2008, the Company's management proceeded in readjusting its main contracts along with re-examining and re-organizing its most significant side businesses. As a result an important increase of revenues appeared in comparison to the previous fiscal year.

<sup>(1)</sup> During the 3<sup>rd</sup> Quarter of 2009, the Company proceeded to leasing areas of a store inside the clinic's building. From this contract (started on 01/11/2009) arose commercial value of €630.000,00 for the parent Company and €930.000,00 for the Group.

Due to the fact that, that are no future obligations or provisions of the owner to the lease holder, the full amount of the benefit was recognized in the current P&L statement.

### **18. Financial cost – net**

	<b>Group 31.12.2008</b>	<b>Group 31.12.2009</b>	<b>Company 31.12.2008</b>	<b>Company 31.12.2009</b>
<b>Financial cost</b>				
- Interest expense	277.671,71	14.864,76	176.921,07	2.811,75
- Debenture loan's interests	6.239.167,33	2.540.779,36	3.453.731,48	1.575.420,68
- Loss from securities depreciation	635.669,38	0,00	635.669,38	0,00
- Other	134.810,48	16.816,42	9.422,52	6.187,56
<b>Total Financial cost</b>	<b>7.287.318,90</b>	<b>2.572.460,54</b>	<b>4.275.744,45</b>	<b>1.584.419,99</b>
<b>Financial income</b>				
- Credit interest	1.136.306,95	431.715,51	324.795,50	83.218,38
- Profit from evaluation at fair value	0,00	87.569,44	0,00	87.569,44
- Dividends	155.165,50	109.827,94	1.164.965,50	867.942,94
- Profit from securities' sale	0,00	0,00	0,00	0,00
<b>Total Financial income</b>	<b>1.291.472,45</b>	<b>629.112,89</b>	<b>1.489.761,00</b>	<b>1.038.730,76</b>

Interests of a total amount of € 337.658,36 regarding the issuance of a debenture loan of the subsidiary company IASO Thessalias, which has not commenced its operating activity yet, since the building of the clinic is still under construction, came up, for the nine month period of 2009. According to the new standards of IAS 23, the aforementioned expense of the borrowings' cost, which is directly related to the clinic's construction, has burdened directly the cost of construction and this is the reason why it is not included in the above table.

The consolidated results do not include dividends, which derive from subsidiaries, and have been collected by the parent company during the fiscal year 2009. The total amount of the aforementioned dividends reaches €765.000,00 and derives entirely from the subsidiary MEDSTEM SERVICES.

### **19. Income tax expense**

The current income tax expense (payable) comes from the deduction of the profits after tax of the non deductible expenses, which mainly include provisions and expenses that

“IASO” PRIVATE GENERAL – OBSTETRIC – GYNECOLOGICAL & PAEDIATRICS CLINIC – DIAGNOSTIC - THERAPEUTIC &  
RESEARCH CENTER S.A.

are not recognized from the tax authorities. The income tax declarations are filed on an annual basis but the profits or losses declared, remain provisional up until the time when the company's tax returns, as well as the books and records are audited by the tax authorities. Tax losses, to the extent that they are recognized by the tax authorities may be used to set-off future profits for the following five years.

	<b>Group 31.12.2008</b>	<b>Group 31.12.2009</b>	<b>Company 31.12.2008</b>	<b>Company 31.12.2009</b>
Current I.F.R.S. tax	<b>14.753.110,49</b>	<b>13.099.140,04</b>	<b>7.930.905,60</b>	<b>9.174.297,09</b>
Deferred Tax adjustments to the offset fiscal year	-5.395.685,32	-3.553.839,28	416.891,34	0,00
Other taxes and duties	-165.164,37	-167.717,43	-78.645,62	-78.645,62
Deferred tax Liability/Receivable	-325.559,93	834.121,24	163.845,57	785.033,98
Tax audit adjustments	-19.602,21	0,00	0,00	0,00
Provision for Tax audit adjustments	-419.366,00	-380.355,54	-359.366,00	-350.355,54
<b>Actual tax charge</b>	<b>8.427.732,66</b>	<b>9.831.349,03</b>	<b>8.073.630,89</b>	<b>9.530.329,91</b>
% of Actual tax charge	0,41	0,49	0,24	0,35

During the fiscal year 2008 all the Group's companies that are subjected to law 3697/2008 accepted the proposed by the Law "settlement without audit" for the unaudited fiscal years 2003-2006.

All of the Group's companies adjusted their tax receivables and liabilities so as, on 31/12/2009, to represent with clarity the Company's and the Group's equity.

For this reason, on 31/12/2009, part of the Group's deferred tax benefits that come from the fiscal year 2004, was written off due to the expiration of the offset tax period.

	<b>IAS Tax</b>	<b>Extraordinary tax contribution of L.3808/2009</b>	<b>Deferred Tax adjustments to the offset fiscal year</b>	<b>Duties for property</b>	<b>Deferred tax Liability/ Receivable</b>	<b>Provision for Tax Audit Adjustments</b>	<b>Current tax charge</b>	<b>Unaudited fiscal years</b>
<b>IASO S.A.</b>	6.803.436,61	2.370.860,48	0,00	-78.645,62	785.033,98	-350.355,54	9.530.329,91	<b>2006-2009</b>
<b>IASO GENERAL S.A.</b>	3.628.548,62	0,00	-3.423.670,92	-62.360,73	-142.516,97	0,00	0,00	<b>2006-2009</b>
<b>MEDSTEM SERVICES S.A.</b>	329.526,31	0,00	0,00	0,00	-48.352,75	-30.000,00	251.173,56	<b>2007-2009</b>
<b>IASO THESSALIAS S.A.</b>	-112.869,29	0,00	-106.970,28	-23.290,44	243.130,01	0,00	0,00	<b>2007-2009</b>
<b>IASO MACEDONIAS S.A.</b>	1.536,77	0,00	0,00	-3.420,64	1.883,87	0,00	0,00	<b>2007-2009</b>
<b>MODERN MULTIFUNCTIONAL CENTER S.A.</b>	19.161,26	0,00	-19.433,31	0,00	272,05	0,00	0,00	<b>2007-2009</b>
<b>IASO HEALTH ENTERPRISE S.A.</b>	3.813,70	0,00	-3.984,77	0,00	171,07	0,00	0,00	<b>2007-2009</b>
<b>IASO OF SOUTHERN SUBURBS S.A.</b>	55.125,58	0,00	220,00	0,00	-5.500,02	0,00	49.845,56	<b>2007-2009</b>

The extraordinary tax contribution according to Law 3808/2009, amounts to €2.370.860,48 and was imposed on the taxed profits of the FY2009. The extraordinary tax notice was communicated to the Company on December 2009. Due to the fact that there were no relevant provisions made, the full amount burdened the current profit and loss statement.

The Company and the Group proceeded to tax audit adjustments provision regarding the unaudited fiscal years, whose cumulative balance, on 31/12/2009, was the following:

<b>Fiscal Year</b>	<b>Group</b>	<b>Company</b>
2006	339.237,35	339.237,35
2007	332.903,32	332.903,32
2008	419.366,00	359.366,00
2009	380.355,54	350.355,54
<b>Total</b>	<b>1.471.862,21</b>	<b>1.381.862,21</b>

## **20. Earnings per share**

### **Basic - Group**

Basic earnings per share are calculated by dividing the profit attributable to equity holders of the Company by the weighted average number of ordinary shares in issue during the year, excluding ordinary shares purchased by the Company and held as treasury shares.

	<b><u>31.12.2008</u></b>	<b><u>31.12.2009</u></b>
Profit attributable to equity holders of the Company (from ongoing operations)	22.638.724,00	13.737.272,98
Weighted average number of ordinary shares in issue (IAS 33)	53.155.053	53.155.053
<b>Basic earnings per share</b>	<b><u>0,4259</u></b>	<b><u>0,2584</u></b>

### **Basic - Company**

Basic earnings per share is calculated by dividing the profit attributable to equity holders of the Company by the weighted average number of ordinary shares in issue during the year, excluding ordinary shares purchased by the Company and held as treasury shares.

	<u>31.12.2008</u>	<u>31.12.2009</u>
Profit attributable to equity holders of the Company (from ongoing operations)	24.589.443,31	17.191.387,64
Weighted average number of ordinary shares in issue (IAS 33)	53.155.053	53.155.053
<b>Basic earnings per share</b>	<b>0,4626</b>	<b>0,3234</b>

The weighted average number of ordinary shares in issue (IAS 33) at 31/12/2009 and 31/12/2008 for the Company and the Group is 53.155.053 shares respectively.

## **21. Dividends per share**

The Shareholders' General Meeting held on 19/06/2009 decided, regarding the dividend of the fiscal year in 2008, the distribution of a dividend equal to € 0,22 per share. Dividend, according to article 18 of Law 3697/2008, is subject to a 10% withholding tax (0,022 per share) and as a consequence shareholders will receive a net dividend amount of €0,198 per share.

Regarding the fiscal year 2009, the Company's management is going to propose to the Shareholders' General Meeting the distribution of a dividend equal to € 0,11 per share. According to IFRS, the aforementioned dividend is included in the Net Equity of the company as at December 31<sup>st</sup> 2009. After the approval of the General Shareholders' Meeting, it will be transferred from the Net Equity to other short-term liabilities. As a result, the net equity as at December 31<sup>st</sup> 2009 includes the dividend of the fiscal year 2009, while the short-term liabilities of December 31<sup>st</sup> 2009 include the dividends of previous years that had not been collected by the shareholders.

## **22. Expenses by nature**

The analysis of the cost distribution for the Company and the Group for the fiscal periods 01.01-31.12.2009 and 01.01-31.12.2008 is the following:

	<u>Company</u> <u>01.01-31.12.2008</u>	<u>Company</u> <u>01.01-31.12.2009</u>	<u>Group</u> <u>01.01-31.12.2008</u>	<u>Group</u> <u>01.01-31.12.2009</u>
Merchandise- Consumables	50.243.808,60	49.435.367,22	16.094.654,32	15.963.353,79
Salaries and fringe benefits	44.285.948,35	48.327.152,90	27.252.348,51	30.055.501,92

Third parties' fees and expenses	28.911.867,69	28.277.358,00	19.895.900,11	19.888.668,91
Third parties' utilities and services	7.221.476,42	7.053.687,42	4.587.488,85	4.163.208,75
Other dues	1.207.455,01	993.797,51	462.752,01	445.348,64
Sundry expenses	5.297.612,31	5.426.676,53	3.369.298,98	3.390.062,08
Interest and similar charges	6.536.210,61	2.572.460,54	3.640.075,07	1.584.419,99
Depreciation of fixed assets charged to operating cost	7.742.951,68	8.956.206,23	4.138.125,09	5.147.300,95
Provisions	2.641.509,83	1.641.821,51	1.323.446,12	428.871,53
Crossing out of consolidated financial statements	-448.689,94	-431.797,00	0,00	0,00
<b>Total</b>	<b>153.640.150,56</b>	<b>152.252.730,86</b>	<b>80.764.089,06</b>	<b>81.066.736,56</b>

The distribution of cost into cost of services, administrative cost, selling cost and financial cost of the Company for the fiscal periods 01.01-31.12.2009 and 01.01-31.12.2008 is the following:

<b>Company 01.01-31.12.2009</b>	<b><u>Cost of services</u></b>	<b><u>Administrative expenses</u></b>	<b><u>Selling cost</u></b>	<b><u>Financial expenses</u></b>	<b><u>Total</u></b>
Merchandise- Consumables	15.746.717,47	97.785,27	118.851,05	0,00	15.963.353,79
Salaries and fringe benefits	26.364.923,51	2.671.818,72	1.018.759,69	0,00	30.055.501,92
Third parties' fees and expenses	19.075.209,98	556.068,26	257.390,67	0,00	19.888.668,91
Third parties' utilities and services	3.799.975,18	214.788,28	148.445,29	0,00	4.163.208,75
Other dues	376.886,06	26.336,31	42.126,27	0,00	445.348,64
Sundry expenses	2.562.300,49	378.628,81	449.132,78	0,00	3.390.062,08
Interest and similar charges	0,00	0,00	0,00	1.584.419,99	1.584.419,99
Depreciation of fixed assets charged to operating cost	4.779.601,89	196.700,31	170.998,75	0,00	5.147.300,95
Provisions	171.249,17	9.033,11	248.589,25	0,00	428.871,53
<b>Total</b>	<b>72.876.863,75</b>	<b>4.151.159,07</b>	<b>2.454.293,75</b>	<b>1.584.419,99</b>	<b>81.066.736,56</b>

<b>Company 01.01-31.12.2008</b>	<b><u>Cost of services</u></b>	<b><u>Administrative expenses</u></b>	<b><u>Selling cost</u></b>	<b><u>Financial expenses</u></b>	<b><u>Total</u></b>
Merchandise- Consumables	15.795.995,00	117.556,59	181.102,73	0,00	16.094.654,32
Salaries and fringe benefits	23.938.801,35	2.294.753,59	1.018.793,57	0,00	27.252.348,51
Third parties' fees and expenses	19.095.627,34	561.738,83	238.533,94	0,00	19.895.900,11
Third parties' utilities and services	3.841.164,34	189.152,49	557.172,02	0,00	4.587.488,85
Other dues	372.499,36	47.153,04	43.099,61	0,00	462.752,01
Sundry expenses	2.517.593,75	396.292,14	455.413,09	0,00	3.369.298,98
Interest and similar charges	0,00	0,00	0,00	3.640.075,07	3.640.075,07
Depreciation of fixed assets charged to operating cost	3.763.729,56	205.789,84	168.605,69	0,00	4.138.125,09
Provisions	400.107,13	21.332,96	266.336,65	635.669,38	1.323.446,12
<b>Total</b>	<b>69.725.517,83</b>	<b>3.833.769,48</b>	<b>2.929.057,30</b>	<b>4.275.744,45</b>	<b>80.764.089,06</b>

The distribution of cost into cost of services, administrative cost, selling cost and financial cost of the Group for the fiscal periods 01.01-31.12.2009 and 01.01-31.12.2008 is the following:

<b>Group 01.01-31.12.2009</b>	<b><u>Cost of services</u></b>	<b><u>Administrative expenses</u></b>	<b><u>Selling cost</u></b>	<b><u>Financial expenses</u></b>	<b><u>Total</u></b>
Merchandise- Consumables	49.111.057,50	158.040,03	166.269,69	0,00	49.435.367,22
Salaries and fringe benefits	42.366.818,59	4.149.468,56	1.810.865,75	0,00	48.327.152,90
Third parties' fees and expenses	27.115.428,03	744.575,49	417.354,48	0,00	28.277.358,00
Third parties' utilities and services	6.343.312,20	447.788,13	262.587,09	0,00	7.053.687,42
Other dues	523.150,82	120.439,27	350.207,42	0,00	993.797,51
Sundry expenses	3.960.357,49	582.309,61	884.009,43	0,00	5.426.676,53
Interest and similar charges	0,00	0,00	0,00	2.572.460,54	2.572.460,54
Depreciation of fixed assets charged to operating cost	8.472.873,26	247.497,94	235.835,03	0,00	8.956.206,23
Provisions	356.103,50	24.794,84	1.260.923,17	0,00	1.641.821,51
Crossing out of consolidated financial statements	-380.969,42	0,00	-50.827,58	0,00	-431.797,00
<b>Total</b>	<b>137.868.131,97</b>	<b>6.474.913,87</b>	<b>5.337.224,48</b>	<b>2.572.460,54</b>	<b>152.252.730,86</b>

<b>Group 01.01-31.12.2008</b>	<b><u>Cost of services</u></b>	<b><u>Administrative expenses</u></b>	<b><u>Selling cost</u></b>	<b><u>Financial expenses</u></b>	<b><u>Total</u></b>
Merchandise- Consumables	49.807.720,86	190.300,02	245.787,72	0,00	50.243.808,60
Salaries and fringe benefits	39.260.170,81	3.180.714,55	1.845.062,99	0,00	44.285.948,35
Third parties' fees and expenses	27.673.908,53	869.442,67	368.516,49	0,00	28.911.867,69
Third parties' utilities and services	6.237.658,32	337.107,51	646.710,59	0,00	7.221.476,42
Other dues	635.203,30	178.686,74	278.126,06	115.438,91	1.207.455,01
Sundry expenses	3.857.229,13	528.058,45	912.324,73	0,00	5.297.612,31
Interest and similar charges	0,00	0,00	0,00	6.536.210,61	6.536.210,61
Depreciation of fixed assets charged to operating cost	7.269.281,34	256.775,47	216.894,87	0,00	7.742.951,68
Provisions	586.000,11	27.093,68	1.392.746,65	635.669,38	2.641.509,83
Crossing out of consolidated financial statements	-447.089,94	0,00	-1.600,00	0,00	-448.689,94
<b>Total</b>	<b>134.880.082,46</b>	<b>5.568.179,09</b>	<b>5.904.570,10</b>	<b>7.287.318,90</b>	<b>153.640.150,56</b>

(\*) Some expenses amounts in the published statement of comprehensive income if the Group, for FY2008, that referred to provisions for bad debts ere reclassified for comparison purposes. More specifically, the amount of €640.982,39 burdened “Selling and Marketing costs” with an equivalent decrease of the “Cost of sales” by €621.564,06 and the “Administrative expenses” by €19.418,33.

This reclassification has not affected the published statement of comprehensive income, sales, minority interests or Group's equity for the year 2008, except for the previously mentioned expense categories at the "Statement of comprehensive income" of the Financial Statements of the previous fiscal year 2008, which are reformed as follows:

<b>Statement of comprehensive income (Group)</b>		
<b>Description</b>	<b>Published amounts (in Euro)</b>	<b>Reformed amounts (in Euro)</b>
Cost of sales	135.501.646,52	134.880.082,46
Gross profit / (loss)	48.495.221,26	49.116.785,32
Administrative expenses	5.587.597,42	5.568.179,09
Selling and Marketing cost	5.263.587,72	5.904.570,10

In addition, due to the recent changes in IFRS imposed from 01/01/2009, the "profit and loss statement" was renamed as "statement of comprehensive income".

In the fiscal year 2008, due to the revaluation that took place by independent evaluators on the Company's property, a negative surplus came up of €283.757,87, which, in the published financial statements, had been posted to the Company's equity. Due to the aforementioned revaluation, the Group figures presented a positive surplus of € 2.060.928,13, from which the amount of € 1.164.928,13 had been posted to the Group's equity, while a surplus of € 896.000,00 had been posted to the "Other Revenues" account of the P&L statement (as income from revaluation of property) of the fiscal year 2008, in order to off-set an earlier deduction though profit and loss of € 2.429.311,20, which took place when IAS was initially implemented (01/01/2005).

As a result of the aforementioned changes, the amount of € 896.000,00 was reclassified on the previous fiscal year, which had been included in the other revenues account of the profit and loss statement to other comprehensive income after taxes of the statement of comprehensive income, while the amounts € -283.757,87 and € 1.164.928,13 were presented in the other comprehensive income after taxes account, of the Company and the Group respectively, affecting by the same amount the total comprehensive income after taxes of the Company and the Group. Due to the aforementioned changes, the minority rights that correspond to the total comprehensive income after taxes of the Group, were reclassified to € -162.570,51 from € -178.279,40 of the previous year's published financial statements. This modification has been included into the Group's previous

year's relative data and has no impact on the published sales and equity amount of the Company and the Group of the year 2008.

### **23. Guarantees**

The Group has liabilities to banks, other guarantees and other matters that arise from its activity. The parent company at 31/12/2009 has granted guarantees to banks for the amount of € 75 million, in favour of its subsidiaries.

### **24. Share capital**

	<b>Number of shares</b>	<b>Share's nominal value</b>	<b>Value of ordinary shares</b>	<b>Above par value</b>	<b>Total</b>
<b>1<sup>st</sup> of January 2009</b>	53.155.053	0,44	23.388.223,32	42.497.459,83	<b>65.885.683,15</b>
Share capital increase	0	0,00	0,00	0,00	<b>0,00</b>
Share capital decrease	0	0,00	0,00	0,00	<b>0,00</b>
<b>31<sup>st</sup> of December 2009</b>	53.155.053	0,44	23.388.223,32	42.497.459,83	<b>65.885.683,15</b>
Weighted average number of shares according to IAS 33	53.155.053	0,44	23.388.223,32	42.497.459,83	<b>65.885.683,15</b>

The Company's share capital is fully paid and is consisted of fifty-three million one hundred fifty-five and fifty-three (53.155.053) common registered shares with a par value of forty-four cents (€0,44) . All issued shares are traded at the Athens Stock Exchange ("Big Capitalization" category).

### **25. Other long-term receivables**

Other long-term receivables of the Company and the Group are presented as follows:

<b>Guarantees</b>	<b>Group</b>		<b>Company</b>	
	<b>31.12.2008</b>	<b>31.12.2009</b>	<b>31.12.2008</b>	<b>31.12.2009</b>
Public Power Corporation	82.060,00	82.060,00	49.360,00	49.360,00
O.T.E.	269,99	2.435,20	269,99	269,99
E.Y.D.A.P.	5.922,63	6.090,63	5.491,00	5.491,00
Medical gas	13.217,58	13.217,58	13.191,17	13.191,17

Buildings	17.929,64	17.390,69	0,00	0,00
Vehicles	14.944,09	24.108,75	6.619,88	11.771,88
Other long-term receivables	671.417,42	756.515,97	0,00	0,00
<b>Total</b>	<b>805.761,35</b>	<b>901.818,82</b>	<b>74.932,04</b>	<b>80.084,04</b>

All the above given guarantees, either to public or to private organisations, concern the operation of the Company and the Group's companies and are claimable at the expiry date of their respective contracts.

Other long-term receivables are recorded in the following fiscal years, when accrued, and mainly concern the operation of the stem cells collection and storage of the subsidiary company "MEDSTEM SERVICES S.A."

## **26. Other non-current liabilities**

Other non-current liabilities of the Company and the Group are presented as follows:

	<b>Group</b>		<b>Company</b>	
	<b>31.12.2008</b>	<b>31.12.2009</b>	<b>31.12.2008</b>	<b>31.12.2009</b>
Received rent guarantees	78.495,63	67.261,99	68.854,75	57.505,42
Unearned and deferred income	4.476.116,13	5.658.899,09	0,00	0,00
<b>Total</b>	<b>4.554.611,76</b>	<b>5.726.161,08</b>	<b>68.854,75</b>	<b>57.505,42</b>

The subsidiary "MEDSTEM SERVICES S.A.", stores cord blood stem cells and pre-collects deferred income. This policy creates long-term liabilities which expire along with the twenty year contracts. The aforementioned long-term revenues will be measured within the period that the above services will be offered.

## **27. Other non-current provisions**

The other non-current provisions refer to the Company's calculated provisions which overcome a fiscal year. They mainly include provisions for pending lawsuits (Note 15 of Financial Statements) and provisions for tax audit adjustments (Note 19 of Financial Statements).

	Group		Company	
	31.12.2008	31.12.2009	31.12.2008	31.12.2009
Provisions for lawsuits	0,00	5.184.235,86	0,00	4.353.106,55
Provision for lease termination indemnity	382.006,79	109.377,12	382.006,79	109.377,12
Provision for tax audit adjustments	1.091.506,67	1.471.862,21	1.031.506,67	1.381.862,21
Other long term provisions	423.390,90	1.241.699,91	423.390,90	454.967,00
<b>Total</b>	<b>1.896.904,36</b>	<b>8.007.175,10</b>	<b>1.836.904,36</b>	<b>6.299.312,88</b>

## 28. Other operating expenses

	Group		Company	
	31.12.2008	31.12.2009	31.12.2008	31.12.2009
Other customer expenses-levies	25.313,70	32.935,37	12.087,77	20.276,78
Losses of fixed assets	6.153,85	142.900,97	5.397,92	6.763,91
Cut-offs and other expenses of insurance funds	733.317,19	1.142.071,89	13.778,77	10.710,52
Provisions for extraordinary contingencies	0,00	5.184.235,86	0,00	4.353.106,55
<b>Total</b>	<b>764.784,74</b>	<b>6.502.144,09</b>	<b>31.264,46</b>	<b>4.390.857,76</b>

The aforementioned provisions for extraordinary contingencies refer to lawsuits of patients and or their inheritors as well as other third party lawsuits (Note 15).

## 29. Reserves at fair value - Other reserves

	Group		Company	
	31.12.2008	31.12.2009	31.12.2008	31.12.2009
Land	34.239.041,03	34.239.041,03	11.274.658,79	11.274.658,79
Buildings	31.517.452,40	31.517.452,40	29.567.607,76	29.567.607,76
<b>Reserves at fair value Total</b>	<b>65.756.493,43</b>	<b>65.756.493,43</b>	<b>40.842.266,55</b>	<b>40.842.266,55</b>
Legal Reserve	6.975.781,65	8.256.157,46	6.480.570,89	7.724.230,95
<b>Other Reserves Total</b>	<b>6.975.781,65</b>	<b>8.256.157,46</b>	<b>6.480.570,89</b>	<b>7.724.230,95</b>

For the cumulative surplus value deriving from the property adjustment to fair value that is demonstrated in the consolidated financial statements of 31/12/2008, was calculated, within the fiscal period, deferred tax liability with estimated tax rate 20% because of the long-term self use of property. As a result the equity of the Company and the Group was decreased by € 10,2 mil. and € 16,44 mil. respectively.

This deferred liability of the Company and the Group was calculated with tax rate 20%, since, according to law 3697/2008 (that was published in 2008) the tax rate for the fiscal years 2010-2014 will be reduced by 1 point per fiscal year.

Other reserves, include the Company's and the Group's legal reserve, which is assessed by the Annual General Meeting's approval of the profits' distribution.

### **30. Events after the balance sheet date**

- The procedure for obtaining the operating license for a General Clinic of the subsidiary company IASO THESSALIAS S.A., was completed in March 2010. Monday 22<sup>nd</sup> of March 2010, has been set as the starting date for the clinic's operation. IASO Group is again a step ahead and responding to the modern needs of the family is starting the operation of the new General – Obstetrics Clinic in the region of Larissa, of total budget €70 mil.
- In January 2010, the management of the subsidiary company IASO THESSALIAS S.A., proceeded in signing a contract for the issuance of a common bond loan up to a maximum amount of € 49 mil., € 30 mil. of which were used for paying the previous bond loan, while the rest will be used for completing the financing of the investment and the interests during the constructing period.

Apart from the above, there are no other events after the 31<sup>st</sup> of December, that concern either the Group or the Company, which should be reported according to IAS.

Maroussi, 19/03/2010

<b>CHAIRMAN OF THE BOARD OF DIRECTORS</b>	<b>MANAGING DIRECTOR</b>	<b>GROUP'S GENERAL MANAGER</b>	<b>GROUP'S CHIEF FINANCIAL OFFICER</b>	<b>GROUP'S CHIEF ACCOUNTING OFFICER</b>
<b>GEORGIOS I. STAMATIOU</b>	<b>PARASKEVAS P. PETROPOULOS</b>	<b>PASCHALIS A. BOUCHORIS</b>	<b>VASSILIOS E. ANASTASSAKIS</b>	<b>STYLIANOS D. TSIROPOULOS</b>
<b>I.D. : K 030874</b>	<b>I.D. : N 317661</b>	<b>I.D. : K 756010</b>	<b>I.D. : AA 58349</b>	<b>I.D. : T 123040</b>
				<b>A' CLASS REG. No 21907</b>

# E. DATA AND INFORMATION FOR THE FISCAL YEAR FROM JANUARY 1<sup>ST</sup> TO DECEMBER 31<sup>ST</sup> 2009

IASO S.A.		PRIVATE GENERAL - OBSTETRIC - GYNECOLOGICAL & PAEDIATRICS CLINIC - DIAGNOSTIC - THERAPEUTIC & RESEARCH CENTER		
		REG. No : 13366/06/06/61		
37-39 Kifissias Ave. 15123 Marousi Athens				
Data and information for the fiscal year from 1 January 2009 to 31 December 2009				
(Published in accordance with L. 2190/1920, article 135, for companies preparing annual financial statements, consolidated or not, according to the IFRS)				
The following data and information aim to provide a general briefing for the financial position and the results of operations of the Group and the Company IASO S.A. Therefore, it is recommended, to any reader, before proceeding to any kind of investment decision or other transaction with the Company, to visit the Company's web site, where the Financial Statements are posted and prepared according to the International Financial Reporting Standards accompanied with the Review Report of the Certified Auditor Accountant where it is necessary.				
<b>INFORMATION CONCERNING THE COMPANY</b>				
Supervising Authority:	Ministry of Development, Department for Limited Companies			
Website address:	www.iaso.gr			
Board of Directors Composition:	Chairman: Georgios Stamatiou A Vice-Chairman: Sotirios Zoumbos B Vice-Chairman: Emmanouil Douglaridas Managing Director: Panagiotis Petropoulos, Emmanouil Floras, Georgios Boukalis Members: Panagiotis Theodorakis, Leonidas Kankalakis, Leonidas Mamas, Nikolaos Stoukalis, Stefanos Chaniotakis Independent Members: Georgios Botoulakis, Spyridon Dimitriadis			
Date of approval of the annual financial statements by the Board of Directors:	19 March 2010			
Certified Auditor Accountant:	Ioanna Tzoupanidou (SOEL Reg. No.12081)			
Auditing Company:	Sak & Tsy Hellen A.E.			
Type of Auditor's Report:	Unqualified Opinion			
<b>STATEMENT OF FINANCIAL POSITION (consolidated and company) (Amounts reported in Euro)</b>				
	<b>THE GROUP</b>	<b>THE COMPANY</b>	<b>THE GROUP</b>	<b>THE COMPANY</b>
	31/12/2009	31/12/2009	31/12/2008	31/12/2008
<b>ASSETS</b>				
Intangible assets	20,754,975.97	28,150,076.40	13,430,126.67	12,933,544.69
Intangible assets	1,536,370.87	1,569,846.26	1,133,347.96	1,012,289.45
Other non-current assets	9,018,812.02	8,071,761.39	123,103,161.00	122,055,692.40
Investments	5,439,971.43	5,469,591.39	2,367,694.08	2,753,990.66
Trade and other receivables	32,782,277.70	34,895,198.95	4,589,503.76	5,137,439.61
Other current assets	43,496,623.33	40,071,494.04	23,039,856.63	22,010,378.51
<b>TOTAL ASSETS</b>	<b>101,678,063.32</b>	<b>107,665,568.11</b>	<b>236,263,685.10</b>	<b>235,895,315.32</b>
<b>EQUITY AND LIABILITIES</b>				
Shareholders Equity (51,199,000 shares x 0.44 €)	20,398,203.32	23,398,220.32	23,398,220.32	20,398,220.32
Other shareholders equity	1,536,370.87	1,569,846.26	1,133,347.96	1,012,289.45
<b>Total Shareholders Equity (A)</b>	<b>21,934,574.19</b>	<b>24,968,066.58</b>	<b>24,531,568.28</b>	<b>21,410,509.77</b>
Minority interest (B)	12,094,000.00	9,799,811.32	0.00	0.00
<b>Long-term liabilities (C)</b>	<b>18,039,387.31</b>	<b>18,345,972.42</b>	<b>36,307,777.07</b>	<b>36,307,777.07</b>
Long-term bank borrowings	17,850,000.00	17,420,000.00	6,750,000.00	66,750,000.00
Provisions/Other long-term liabilities	189,387.31	925,972.42	25,557,777.07	29,557,777.07
Short-term bank borrowings	20,000,000.00	8,000,000.00	5,500,000.00	5,500,000.00
Other short-term liabilities	29,832,349.04	66,447,546.67	30,191,220.71	29,011,119.61
<b>Total Liabilities (D)</b>	<b>78,743,487.13</b>	<b>75,297,801.83</b>	<b>72,731,917.07</b>	<b>71,784,745.67</b>
<b>TOTAL EQUITY AND LIABILITIES (A)+(B)+(C)+(D)</b>	<b>101,678,063.32</b>	<b>107,665,568.11</b>	<b>236,263,685.10</b>	<b>235,895,315.32</b>
<b>STATEMENT OF COMPREHENSIVE INCOME (consolidated and company) (Amounts reported in Euro)</b>				
	<b>THE GROUP</b>	<b>THE COMPANY</b>	<b>THE GROUP</b>	<b>THE COMPANY</b>
	1/1-31/12/2009	1/1-31/12/2009	1/1-31/12/2008	1/1-31/12/2008
Sales	17,431,272.02	15,112,028.78	11,513,112.04	10,411,920.00
Costs (profit/loss)	(16,498,627.02)	(13,599,697.79)	(10,527,701.28)	(10,021,180.43)
Gross profit/loss	932,645.00	1,512,330.99	985,410.76	390,739.57
Operating expenses, financing and investing results (EIT)	(28,598,644.83)	(41,194,182.30)	(24,911,372.06)	(24,900,006.23)
Profit/loss before taxes	(27,666,000.00)	(42,171,851.31)	(23,925,961.30)	(24,509,266.66)
Profit/loss after taxes (A)	(27,666,000.00)	(42,171,851.31)	(23,925,961.30)	(24,509,266.66)
Other Comprehensive Income (OCI)				
OCI of the Company	13,337,272.02	23,679,734.54	17,191,267.64	24,673,310.18
OCI of the Company	(2,211,158.86)	(204,542.98)	0.00	0.00
OCI of the Company	0.00	2,099,328.13	0.00	(281,787.87)
<b>Total Comprehensive Income after taxes (A)+(B)</b>	<b>(16,549,826.84)</b>	<b>(41,273,664.74)</b>	<b>(7,734,693.66)</b>	<b>(24,509,266.66)</b>
OCI of the Company	13,337,272.02	23,679,734.54	17,191,267.64	24,673,310.18
OCI of the Company	(2,211,158.86)	(204,542.98)	0.00	0.00
OCI of the Company	0.00	2,099,328.13	0.00	(281,787.87)
Earnings/loss after taxes per share - basic (in Euro)	0.2594	0.4259	0.3204	0.4626
Proposed dividend per share (in Euro)	0.0000	0.0000	0.0000	0.0000
Earnings/loss before taxes, financing and investing results and depreciation-amortization (EITDA)	37,514,801.86	49,397,933.98	32,056,674.91	33,728,216.38
<b>ADDITIONAL DATA AND INFORMATION</b>				
The Companies of the Group with their respective addresses and participation percentages that are included in the consolidated Annual Financial Statements (Note 6.2) are:				
<b>COMPANY NAME</b>	<b>Registered Office</b>	<b>Unaudited fiscal years</b>	<b>% of participation</b>	<b>Participation relationship</b>
1. IASO S.A.	Greece, Marousi, Attiki	2006-2009	100.00%	Parent
2. IASO GENERAL CLINIC OF HOLARGOS SA	Greece, Holargos, Attiki	2006-2009	97.07%	Direct
3. IASO MACEDONIAS HEALTH GROUP OF NORTHERN GREECE SA	Greece, Marousi, Attiki	2007-2009	100.00%	Direct
4. IASO OF SOUTHERN SUBURBS GENERAL CLINIC-PRIVATE OBSTETRICS SA	Greece, Marousi, Attiki	2007-2009	53.43%	Direct & Indirect
5. MODERN MULTIFUNCTIONAL REHABILITATION/RESTORATION CENTER SA	Greece, Marousi, Attiki	2007-2009	99.97%	Direct & Indirect
6. IASO HEALTH ENTERPRISES SA	Greece, Marousi, Attiki	2007-2009	99.97%	Direct & Indirect
7. IASO MEDICAL SERVICES SA	Greece, Marousi, Attiki	2007-2009	99.97%	Direct & Indirect
8. IASO THESSALIA GENERAL CLINIC-PRIVATE OBSTETRICS SA	Greece, Larissa	2007-2009	75.69%	Direct & Indirect
No changes occurred after its completion in the method of consolidation in the Annual Financial Statements from 01.01.2008 to today.				
1. The accounting principles applied in these Annual Financial Statements are the same as those applied in the Financial Statements of 31.12.2008.				
2. On the assets of the Company and the Group there are no pledges, apart from the subsidiary IASO GENERAL CLINIC OF HOLARGOS SA, where there is a prohibition against its fixed assets amounting to € 54,000,000.00 for securing a debt bank loan of € 45,000,000.00, whose unpaid balance at 31.12.2009 amounted to € 25,000,000.00.				
3. The number of employees are as follows: Company 1,019 and 1,008 at 31.12.2009 and 31.12.2008 respectively, Group 1,701 and 1,669 at 31.12.2009 and 31.12.2008, respectively.				
4. The earnings per share were calculated on the basis of the profit after taxes and minority interest divided by the weighted average number of the parent Company's ordinary shares.				
5. The investments of the Group for the period 01.01.12.2009 for tangible and intangible assets amounted to € 40,259,954.49 while those of the Company amounted to € 9,907,462.72.				
6. The Company and the Group have made a cumulative provision for tax losses and penalties, for the unutilized tax loss carryforwards, amounting to € 1.38 ml. and € 1.47 ml. respectively (More details in Note 19 of the Financial Statements).				
7. There are third party lawsuits for indemnities against the Company and the Group for an initial total claim of about € 197.72 ml. and € 175.06 ml. respectively. Even though the final outcome of these cases cannot be predicted at present, the Company and the Group have made a cumulative provision, in the Financial Statements of 31/12/2009, of approximately € 4.26 and € 5.10 respectively, which burden and result and equity (Note 15 of the Financial Statements).				
8. The Company and the Group have made a cumulative provision of € 6,836,406.01 and € 10,929,141.29 respectively, up until 31.12.2009, in "other provisions" (liability benefit obligations and doubtful receivables).				
9. The statement of comprehensive income of the Company and the Group at 31.12.2009, does not include income and expenses that are included in "other revenue" account as indicated by the revised IAS 1 or allowed by IAS 19, while the statement of comprehensive income of the Company and the Group at 31.12.2008 includes the amounts of € -280,747.87 and € 2,950,309.10 respectively, which concern the revaluation of subsidiary property (Note 20 of the Financial Statements).				
10. On 03.05.2009, the share capital increase of the subsidiary company "IASO THESSALIA GENERAL CLINIC-PRIVATE OBSTETRICS S.A." was completed through cash payment with pre-emption rights in favor of the existing shareholders. The aforementioned share capital increase was decided on 01.11.2008 by the Extraordinary Shareholders Meeting of this company and took place from 01.11.2008 until 03.05.2009. Following that, the share capital of the company was increased by € 4,857,144.00 through the issuance of 2,428,572 new common registered shares with voting rights, of nominal value € 2.00 per share. The par value of the shares issued, amounting € 4,857,144.00, is recognized as "share premium" in shareholders equity.				
11. At the end of the current period, no shares of the parent Company were in possession neither of the parent Company nor of its subsidiaries and related companies.				
12. Upon resolution of the Extraordinary Meeting of shareholders of the subsidiary company "IASO THESSALIA GENERAL CLINIC-PRIVATE OBSTETRICS S.A." held on 04.04.2009, it was decided to increase the share capital by € 5,490,324.00 by cash, through the issuance of 2,745,162 new registered shares of nominal value € 2.00 each and issue price € 2.00. The issuing Share Premium Reserve amounted to € 4,119,993.00. (Details: 10/09/09, 09.2009 of Larissa Prefecture).				
13. Upon resolution of the General Meeting of shareholders of the subsidiary company "IASO OF SOUTHERN SUBURBS S.A.", held on 18.06.2009, it was decided to decrease the nominal value of shares from € 500 to € 0.25 (with a simultaneous increase due to this decrease of 20,000 new common listed registered shares (0.25% of nominal value € 2.00 each) and as a result the total number of shares increased from 2,012,000 common listed registered shares to 40,000 common registered shares with voting rights of € 2.00 each.				
14. Some of the amounts included in the statement of comprehensive income of the fiscal year 2009 were reversed due to computation and presentation reasons. These changes have not affected revenues and equity of the previous year's published Financial Statements, while the changes that came up from reclassification of earnings/loss after taxes and minority interests, as well as those of the comprehensive income after taxes of the Company and the Group, are presented in Note 20 of the Annual Financial Statements.				
15. The Company's Board of Directors is going to propose to the Shareholders' General Meeting the distribution of a dividend equal to € 0.11 per share.				
16. The accumulated amounts of purchases and sales (including revenues by dividends) from the beginning of the period until the end of the period, that arise from the Company's transactions with related parties according to IAS 24, are as follows:				
	<b>Group</b>	<b>Company</b>		
a) Revenues	0.00	1,010,478.02		
b) Expenses	(693,460.61)	(940,101.96)		
c) Receivables	0.00	(243,320.89)		
d) Liabilities	0.00	199,098.16		
e) Remuneration to BoD members and managers	1,911,094.58	1,101,106.36		
f) Receivables from BoD members and managers	0.00	0.00		
g) Payables to BoD members and managers	0.00	0.00		
Marousi 19 March 2010				
<b>CHAIRMAN OF THE BOARD OF DIRECTORS</b>	<b>MANAGING DIRECTOR</b>	<b>GROUP GENERAL MANAGER</b>	<b>GROUPS CHIEF FINANCIAL OFFICER</b>	<b>CHIEF ACCOUNTING OFFICER</b>
GEORGIOS I. STAMATIOU I.D.: K 030874	PANAKYVAS P. PETROPOULOS I.D.: N 317641	PASCHALIS A. BOUCHORS I.D.: K 785910	VASSILIOS E. ANASTASSIADIS I.D.: AA 53049	STYLINOS D. YSIROPOULOS I.D.: T 123040A CLASS REG. No 2 1997

## F. INFORMATION REGARDING article 10 of L.3401/2005

The table below incorporates the information of Article 10 Law 3401/2005, which the Company has published and made available to the public during the year 2009.

### INVITATIONS & RESOLUTIONS OF GENERAL SHAREHOLDERS' MEETINGS

24/06/2009	Resolutions of the Shareholders' Annual General Meeting	<a href="http://www.iaso.gr/Investor Relations/Notifications to ATHEX &amp; HCMC / 2009">www.iaso.gr/Investor Relations/ Notifications to ATHEX &amp; HCMC / 2009</a>
28/05/2009	Invitation to the Annual Ordinary General Meeting	""

### FINANCIAL STATEMENTS & ANNOUNCEMENTS

27/03/2009	Financial results for the fiscal year 2008	<a href="http://www.iaso.gr/Investor Relations/Notifications to ATHEX &amp; HCMC / 2009">www.iaso.gr/Investor Relations/ Notifications to ATHEX &amp; HCMC / 2009</a>
30/11/2009	Data & Information Parent Company & Group as of 30.09.2009	<a href="http://www.iaso.gr/Investor Relations/Financial Statements / Parent Company - Group">www.iaso.gr/Investor Relations/ Financial Statements / Parent Company - Group</a>
30/11/2009	Interim Financial Statements Parent Company & Group as of 30.09.2009	""
29/08/2009	Six Month Financial Report of the period 01.01.2009-30.06.2009	""
29/08/2009	Data & Information Parent Company & Group as of 30.06.2009	""
29/05/2009	Data & Information Parent Company & Group as of 31.03.2009	""
29/05/2009	Interim Financial Statements Parent Company & Group as of 31.03.2009	""
30/03/2009	Data & Information Parent Company & Group as of 31.12.2008	""
30/03/2009	Annual Financial Report of FY 2008	""

### CORPORATE ACTIONS & DIVIDENDS

26/06/2009	Announcement regarding the Dividend Distribution	<a href="http://www.iaso.gr/Investor Relations/Notifications to ATHEX &amp; HCMC / 2009">www.iaso.gr/Investor Relations/ Notifications to ATHEX &amp; HCMC / 2009</a>
27/02/2009	Postponement of the sale of fractional shares	""
24/02/2009	Announcement for the sale of fractional shares	""

### OTHER ANNOUNCEMENTS

31/12/2009	Notification of change in managerial positions	<a href="http://www.iaso.gr/Investor Relations/Notifications to ATHEX &amp; HCMC / 2009">www.iaso.gr/Investor Relations/ Notifications to ATHEX &amp; HCMC / 2009</a>
15/09/2009	Notification of change in managerial positions	""
06/07/2009	Comments on a Press Publication	""
25/06/2009	Notification of change in managerial positions	""
24/06/2009	Formation of the new Board of Directors	""
26/05/2009	Announcement regarding IASO of Southern Suburbs S.A.	""
18/05/2009	Notification of change in managerial positions	""
08/04/2009	Notification of change in managerial positions	""
30/03/2009	Press Release: Agreement between IASO of Southern Suburbs S.A. and INTRAKAT S.A.	""
10/03/2009	Notification of change in managerial positions	""
06/03/2009	Comments on a Press Publication	""

### ANNUAL BULLETIN – CORPORATE PRESENTATIONS

09/12/2009	IASO's Participation in the Roadshow Organized by National P&K Securities 11/12/2009	<a href="http://www.iaso.gr/Investor Relations/Notifications to ATHEX &amp; HCMC / 2009">www.iaso.gr/Investor Relations/ Notifications to ATHEX &amp; HCMC / 2009</a>
22/05/2009	Annual Analysts' Briefing	""
13/05/2009	Announcement regarding the Annual Analysts' Briefing	""
10/06/2009	Annual Financial Report 2008	<a href="http://www.iaso.gr/Investor Relations/Annual Bulletins">www.iaso.gr/Investor Relations/ Annual Bulletins</a>

11/12/2009	Corporate Presentation	www.iaso.gr/Investor Relations/ Corporate Presentations
22/05/2009	Annual Analysts' Briefing	""
22/05/2009	FY2008 Results Presentation	""

## **TRADE ACKNOWLEDGEMENTS**

31/12/2009	Announcement of Regulated Information according to L.3556/2008	www.iaso.gr/Investor Relations/ Notifications to ATHEX & HCMC / 2009
29/12/2009	Announcement of Regulated Information according to L.3556/2008	""
11/12/2009	Announcement of Regulated Information according to L.3556/2008	""
27/11/2009	Announcement of Regulated Information according to L.3556/2008	""
25/11/2009	Announcement of Regulated Information according to L.3556/2008	""
17/11/2009	Announcement of Regulated Information according to L.3556/2008	""
04/09/2009	Announcement of Regulated Information according to L.3556/2008	""
13/07/2009	Announcement of Regulated Information according to L.3556/2008	""
28/05/2009	Announcement of Regulated Information according to L.3556/2008	""
24/02/2009	Announcement of Regulated Information according to L.3556/2008	""
09/02/2009	Announcement of Regulated Information according to L.3556/2008	""
05/02/2009	Announcement of Regulated Information according to L.3556/2008	""
05/02/2009	Announcement of Regulated Information according to L.3556/2008	""
29/01/2009	Announcement of Regulated Information according to L.3556/2008	""
28/01/2009	Announcement of Regulated Information according to L.3556/2008	""
08/01/2009	Announcement of Regulated Information according to L.3556/2008	""
07/01/2009	Announcement of Regulated Information according to L.3556/2008	""

## **G. ACCESSIBILITY TO THE FINANCIAL STATEMENTS**

The Group's and the Company's Annual Financial Statements, the financial statements of the consolidated companies, the Auditors' Reports and the Managements' Reports of the Boards of Directors of all consolidated companies, for the fiscal year ended on 31/12/2009, have been posted on the internet, at the address [www.iaso.gr](http://www.iaso.gr).